PF-[ADDRESS_1090716] 
CROSSOVER STUDY EVALUATING THE ABUSE POTENTIAL OF NEURONTIN® 
TAKEN ORALLY CONCOM ITANTLY WITH OXYCODONE HYDROCHLORIDE  
IN HEALTHY NON -DRUG DEPENDENT , RECRE ATIONAL OPI[INVESTIGATOR_791228] : PF-[ADDRESS_1090717] Name:  [CONTACT_591856]® (gabapentin ) 
[LOCATION_002]  (US)  Investigational New 
Drug (IND)  Number:  [ZIP_CODE] , [ZIP_CODE]  
European Clinical Trial s Database 
(EudraCT) Number:  Not Applic able (N/A)  
Protocol Number:  A9451180  
Phase:  4 
Short Title:  Evaluating the Abuse Potential of Neurontin When Taken Orally 
Concomitantly with Oxycodone Hydrochloride in Healthy Non -drug Dependent, 
Recreational Opi[INVESTIGATOR_791229]:  Upjohn US [ADDRESS_1090718]  
[LOCATION_001], NY [ZIP_CODE] -5703  
Sponsor Contacts:   
 
 
 
 
  
 
 
  
 
 
 
  
 
 
This document and accompanying materials contain confidential infor mation belonging to Upjohn .  Except 
as otherwise agreed to in writing, by [CONTACT_185586] s, you agree to hold this 
information in confidence and not copy or disclose it to others (except where required by [CONTACT_1289]) or 
use it for  unauthorized purposes.  I n the event of any actual or suspected breach of this obligation, Upjohn  
must be promptly notified.  
 
  

PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 2  
 PROTOCOL APPROVAL – SPONSOR SIGNATORY  
Study Title  A phase 4, randomized, double -blind, double -dummy, placebo -and 
active -contro lled, single -dose, six -way crossover study evaluating the 
abuse potential of Neurontin® taken orally concomitantly with 
Oxycodone hydrochloride In healthy non -drug dependent, 
recreational opi[INVESTIGATOR_791230]  A9451180  
Amendment No.  2.0  
Protoco l Date  12 March  2021   
 
Protocol accepted and approved by:  
 
[CONTACT_791268]-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 3  
 Protocol Amendment Summary of Changes Table  
Documen t History  
Document  Version Date  Summary of Changes  and Rationale  
Amendment 2  12 March  2021  • Clarifi cations and typographic changes 
for harmonization within the protocol 
were implemented.  
Complete summary of changes is provided 
in Appendix  10.12 
Amendmen t 1 24 December 2020  • The sponsor for this study is changed 
from ‘[COMPANY_007]’ to ‘Upjohn US 1 LLC’  
• Administrative and typographic 
changes for harmonization within the 
protocol were implemented.  
Complete summary of changes is provided 
in Appendix 10.12  
Original  Protocol  09 Novem ber 2020 Not applicable ( N/A) 
PF-[ADDRESS_1090719] OF FIGURES  ................................ ................................ ................................ ................... 9 
1. PROTOCOL SUMMARY  ................................ ................................ ................................ ...10 
1.1. Synopsis (Not Applicable)  ................................ ................................ ...................... 10 
1.2. Schema  ................................ ................................ ................................ .................... 10 
1.3. Schedule of Activities (SoA)  ................................ ................................ ................... 11 
2. INTRODUCTION  ................................ ................................ ................................ ............... 16 
2.1. Study Rationale  ................................ ................................ ................................ .......16 
2.2. Background  ................................ ................................ ................................ ............. 16 
2.2.1.  Clinical Overview  ................................ ................................ ....................... 17 
2.3. Benefit/Risk Assessment  ................................ ................................ ......................... 18 
3. OBJECTIVES AND ENDPOINTS  ................................ ................................ ..................... 18 
4. STUDY DESIGN ................................ ................................ ................................ ................. 20 
4.1. Overall Design  ................................ ................................ ................................ ......... 20 
4.1.1.  Screening  ................................ ................................ ................................ ....21 
4.1.2.  Qualification Phase (Visit 2; Days 0 to 3)  ................................ .................. 21 
[IP_ADDRESS].  Naloxone Challen ge (Day 0)  ................................ ..................... 21 
[IP_ADDRESS].  Instrument Training  ................................ ................................ ...21 
[IP_ADDRESS].  Drug Discrimination  (Days 1 to 3)  ................................ ............ 21 
4.1.3.  Treatment Phase (Visits 3 to 8)  ................................ ................................ ..22 
4.2. Scientific Rationale for Study Design  ................................ ................................ .....23 
4.3. Justification for  Dose  ................................ ................................ .............................. 23 
4.4. End of Study Definition  ................................ ................................ .......................... 24 
5. STUDY POPULATION  ................................ ................................ ................................ ......24 
5.1. Inclusion Criteria  ................................ ................................ ................................ .....24 
5.2. Exclusion Criteria  ................................ ................................ ................................ ....25 
5.3. Lifestyle Considerations  ................................ ................................ .......................... 28 
5.3.1.  Meals and Dietary Res trictions  ................................ ................................ ...28 
5.3.2.  Caffeine, Alcohol, and Tobacco  ................................ ................................ .28 
5.3.3.  Activity  ................................ ................................ ................................ .......29 
5.3.4.  Contraception  ................................ ................................ .............................. 29 
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 5  
 5.4. Screen Failures  ................................ ................................ ................................ ........ 29 
6. STUDY INTERVENTION  ................................ ................................ ................................ ..29 
6.1. Study Interventions Administered  ................................ ................................ ........... 29 
6.1.1.  Administration  ................................ ................................ ............................ 30 
6.2. Preparation/Hand ling/Storage/Ac countability  ................................ ........................ 30 
6.2.1.  Preparation and Dispensing  ................................ ................................ ........ 31 
6.3. Measures to Minimize Bias: Randomization and Blinding ................................ .....[ADDRESS_1090720]  ................................ ......................... 31 
6.3.2.  Breaking the Blind  ................................ ................................ ...................... 32 
6.4. Study Intervention Compliance  ................................ ................................ ............... 32 
6.5. Concomitant Therapy  ................................ ................................ .............................. 33 
6.6. Dose Modification  ................................ ................................ ................................ ...33 
6.7. Emergency Intervention  ................................ ................................ .......................... 33 
6.8. Intervention After the En d of the Study  ................................ ................................ ..33 
7. DISCONTINUATION OF STUD Y INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  ................................ ................................ ........... 34 
7.1. Discontinuation of Study Intervention  ................................ ................................ ....34 
7.2. Participant Disconti nuation/Withdrawal from the Study  ................................ ........ [ADDRESS_1090721] to Follow up  ................................ ................................ ................................ ....36 
8. STUDY ASSESSMENTS AND PROCEDURES  ................................ ............................... 37 
8.1. Efficacy Assessments (Not applicable)  ................................ ................................ ...38 
8.2. Safety Assessments  ................................ ................................ ................................ .38 
8.2.1.  Physical Examination s ................................ ................................ ................ 38 
8.2.2.  Vital Signs  ................................ ................................ ................................ ..39 
[IP_ADDRESS].  Respi[INVESTIGATOR_591788]  ................................ ............................. 40 
[IP_ADDRESS].  Temperature  ................................ ................................ .............. 40 
8.2.3.  Pupi[INVESTIGATOR_115726]  ................................ ................................ ............................... 40 
8.2.4.  Electrocardiograms  ................................ ................................ ..................... 40 
[IP_ADDRESS].  Continuous Cardiac Monitoring by [CONTACT_336258]  ......................... 41 
8.2.5.  Clinical Safety Laboratory Assessments  ................................ .................... 41 
8.2.6.  Suicidal Ideation and B ehavior Risk Monitoring  ................................ .......42 
[IP_ADDRESS]. Columbia Suicidality Severity Rating Scale (C -SSRS)  ............ 42 
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 6  
 [IP_ADDRESS].  Risk Assessment During Screening  ................................ .......... 42 
[IP_ADDRESS].  Risk Assessment During the Study  ................................ ........... 43 
8.2.7.  Pregnancy Testing  ................................ ................................ ...................... 43 
8.3. Adverse Events and Serious Adverse Events  ................................ .......................... 43 
8.3.1.  Time Period and Frequency for Collecting AE and SAE Information  .......44 
[IP_ADDRESS].  Reporting SAEs to [COMPANY_007] Safety  ................................ ............... 44 
[IP_ADDRESS].  Recording Non -serious AEs and SAEs on the CRF  ................. 44 
8.3.2.  Method of Detecting AEs and SAEs  ................................ .......................... 45 
8.3.3.  Follow -up of AEs and SAEs  ................................ ................................ .......45 
8.3.4.  Regulatory Reporting Requirements for SAEs  ................................ ........... 45 
8.3.5.  Exposure During Pregnancy or Breastfeeding, and Occupational 
Exposure  ................................ ................................ ................................ .......... 46 
[IP_ADDRESS].  Exposure During Pregnancy  ................................ ...................... 46 
[IP_ADDRESS].  Exposure During Breastfeeding  ................................ ................ 46 
[IP_ADDRESS].  Occupatio nal Exposure  ................................ ............................. 46 
8.3.6.  Medication Errors  ................................ ................................ ....................... 46 
8.4. Treatment of Overdose  ................................ ................................ ............................ 47 
8.5. Pharmacokinetics  ................................ ................................ ................................ ....48 
8.6. Pharmacodynamics  ................................ ................................ ................................ ..49 
8.6.1.  Subjective  Effects  ................................ ................................ ....................... 49 
[IP_ADDRESS].  Visual  Analog  Scale  (VAS)  ................................ ....................... 49 
8.7. Genetics  ................................ ................................ ................................ ................... 49 
8.7.1.  Specified Genetics  ................................ ................................ ...................... 49 
8.7.2. Banked Biospecimens for Genetics  ................................ ............................ 49 
8.8. Biomarkers  ................................ ................................ ................................ .............. 50 
8.9. Health Economics  ................................ ................................ ................................ ...50 
9. STATISTICAL CONSIDERATIONS  ................................ ................................ ................ 50 
9.1. Statistical Hypothesis  ................................ ................................ .............................. 50 
9.2. Sample Size Determination  ................................ ................................ ..................... 51 
9.3. Populations for Analysis  ................................ ................................ ......................... 52 
9.4. Statistical Analyses  ................................ ................................ ................................ .53 
9.4.1.  Endpoint Analysis  ................................ ................................ ....................... 53 
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 7  
 9.4.2.  Study Validity of Analysis of Endpoints  ................................ .................... 54 
9.4.3.  Analysis of Primary and Secondary Endpoint  ................................ ............ 54 
[IP_ADDRESS].  Pharmacodynamic Analysis  ................................ ...................... 56 
[IP_ADDRESS].  Pharmacokinetic Analysis  ................................ ......................... 57 
9.4.4.  Efficacy Analyses  ................................ ................................ ....................... 58 
9.4.5.  Safety Analyses  ................................ ................................ .......................... 58 
[IP_ADDRESS].  Electrocardiogram Analyses ................................ ...................... 59 
9.4.6.  Exploratory Analyses  ................................ ................................ .................. 59 
9.5. Interim Analyses  ................................ ................................ ................................ .....59 
9.6. Data Monitoring Committee  ................................ ................................ ................... 59 
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  ................................ ................................ ................................ .......... 60 
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight Considerations  ............... 60 
10.1.1.  Regulatory  and Ethical Considerations  ................................ .................... 60 
[IP_ADDRESS].  Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP  ................................ ................................ ......... 61 
10.1.2.  Financial Disclosure  ................................ ................................ ................. 61 
10.1.3.  Informed Consent Process  ................................ ................................ ........ 61 
10.1.4.  Data Protection  ................................ ................................ ......................... 62 
10.1.5.  Dissemination of Clinic al Study Data  ................................ ...................... 62 
10.1.6.  Data Quality Assurance  ................................ ................................ ............ 63 
10.1.7.  Source Documents  ................................ ................................ .................... 65 
10.1.8.  Study and Site Closure ................................ ................................ .............. 65 
10.1.9.  Publication Policy  ................................ ................................ ..................... 65 
10.1.10.  Sponsor’s Qualified Medical Personnel  ................................ ................. 66 
10.2.  Appendix 2:  Clinical Laboratory Tests  ................................ ................................ .67 
10.3.  Appendix 3:  Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting  ................................ ................................ ......69 
10.3.1.  Definition of AE  ................................ ................................ ....................... 69 
10.3.2.  Definition of SAE  ................................ ................................ ..................... 70 
10.3.3.  Recording/Reporting and Follow -up of AEs and/or SAEs ....................... 71 
10.3.4.  Reporting of SAEs  ................................ ................................ .................... 74 
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 8  
 10.4.  Appendix 4:  Contraceptiv e Guidance and Collection of Pregnancy 
Information  ................................ ................................ ................................ ................ 76 
10.4.1.  Male Participant Reproductive Inclusion Criteria  ................................ ....76 
10.4.2.  Female Par ticipant Reproductive Inclusion Criteria  ................................ .76 
10.4.3.  Woman of Childbearing Potential (WOCBP)  ................................ .......... 77 
10.4.4.  Contraception Methods  ................................ ................................ ............. 78 
10.5.  Appendix 5: Genetics  ................................ ................................ ............................ 80 
10.6.  Appendix 6: Liver Safety : Suggested Actions and Follow -up Assessments  ........ 81 
10.7.  Appendix 7: ECG Findings of Potential Clinical Concern  ................................ ...83 
10.8.  Appendix 8: Clinical Opi[INVESTIGATOR_591789]  ................................ ....................... 85 
10.9.  Appendix 9: VAS Assessment Methods  ................................ ............................... 87 
10.10.  Appendix 10: Alternative Measures During Public Emergencies ....................... 91 
10.10.1.  Eligibility  ................................ ................................ ................................ 91 
10.10.2.  Telehealth Visits  ................................ ................................ ..................... 91 
10.10.3.  Alternative Facilities for Safety Assessments  ................................ ........ 91 
10.10.4.  Study Intervention  ................................ ................................ .................. 91 
10.10.5.  Home Health Visits  ................................ ................................ ................. 91 
10.10.6.  Adverse Events and  Serious Adverse Events  ................................ ......... 91 
10.10.7.  Efficacy Assessments  ................................ ................................ ............. 91 
10.10.8.  Independent Oversight Committees  ................................ ....................... 91 
10.11.  Appendix 11: Abbreviations  ................................ ................................ ............... 92 
10.12.  Appendix 12 Summary of Changes  ................................ ................................ ....96 
Section [IP_ADDRESS]  Risk Assessment During Screening  ............................. [ADDRESS_1090722] OF FIGURES  
Figure 1.  Study Schema  ................................ ................................ ........................... 10 
 
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 10  
 1. PROTOCOL SUM MARY  
1.1. Synopsis (Not Applicable)  
1.2. Schema  
The participants will be screened, undergo a Naloxone Challenge to ensure that they are not 
drug dependent and a drug discrimination test to demonstrate that they can differentiate 
between a positive control and placeb o.  Once the participant has passed these tests, they may 
be enrolled into the Treatment Phase of the study.  The Treatment Phase of the  study will use 
a Williams square study design involving approximately 60 adult male and female (at least 
20% females) participants (10 participates in each sequence) in the Treatment Phase to 
ensure at least 48 participan ts complete the  Treatment Phase of the study  as shown in   
Figure 1.  Drop out participant s for non -safety reasons in the Treatmen t Phase can be 
replaced at the discretion of  the Investigator  in consultation with the Sponsor .  
Figure 1. Study Schema  

PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 11  
 1.3. Schedule of Activities  (SoA)  
The SoA table s (Table 1 and Table 2) provides an overview of the protocol visits and procedures.  Refer to the STUDY 
ASSESSMENTS AND PROCEDURES  section of the protocol for detailed information on each procedure and assessment required 
for compl iance with the protocol.   
The investigator may sche dule visits (unplanned visits) in addition to those listed in the SoA table , to conduct evaluations or 
assessments required to p rotect the well -being of the participant .  
Table 1. Schedule of Activities for Screening, Naloxone Challenge and Qualification Phase  
 Visit 1  
Screening  Visit 2 (Qualification Phase)  
 
Naloxone  
Challenge  Drug Discrimination  
Study Day  Within 
28 Days (Day  -
28 to Day -1) Day [ADDRESS_1090723] Dose    Pre-
dose  0 0.25 0.5 1 1.5 2 2.5 3 3.5 4 5 24 
Clinical Research Unit  (CRU ) 
admission   Xa -> -> -> -> -> -> -> -> -> ->- -> ->  
Informed consent  Xo               
Inclusion/Exclusion  X               
Demographics  X               
Medical history (including drug 
abuse)  X X              
Ongoing eligibility review  X X             X 
Prior/Concomitant medication 
(includin g past year recreational drug 
history)  X -> -> -> -> -> -> -> -> -> -> -> ->  -> -> 
Physical examinationb X X             X 
Safety laboratory tests  X X              
HIV, HBsAg, HBcAb, HCVAb , 
HAV IgM, HAV IgG  X               
Urine drug testing  X X              
Serum Pregnancy test (WOCBP  only)  Xc               
Follicular stimulating hormone (FSH)  Xd               
Urine P regnancy test ( WOCBP  only)   Xe              
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 12  
 Contraception check  X               
Alcohol breathalyzer  or urine  X X              
Vital signsf X Xg X  X X X X X       
Pulse oximetry, SpO 2   X  X X X X X X X X X X  
Respi[INVESTIGATOR_697]    X  X X X X X X X X X X  
12-lead Electrocardiogramh X X              
Randomization for Quali fication  
Phase, Day 1    Xr             
Pharmacodynamic (instrument) 
trainingq  X              
Cardiac telemetryi   -> -> -> -> -> -> -> ->      
Pupi[INVESTIGATOR_115726]    X  X X X X X X X X X X  
Study treatment administered   Xj  X            
Visual Analogue Scalesk   Xk(a)  X X X X X X X X X X  
“Take Drug Again ” VAS, “Overall 
Drug  Liking ” VAS               X  
Clinical Opi[INVESTIGATOR_2433] 
(COWS)   Xl              
Serious and non -serious a dverse 
eventsm X X -> -> -> -> -> -> -> -> -> -> -> -> X 
Columbia Sui cide-Severity R ating 
Scale* X X             X 
Evaluate to proceedn  X             X 
Discharge from CRU                X 
a. Admission should  occur in the morning to ensure adequate time for pre -dose review of clinical laboratory results.  
b. Complete physical examination (PE) (including height and weight) only needs to be done once, ie, at Screening or at Day [ADDRESS_1090724] be 
performed at Screening to obtain BMI for determination of eligibility.  A brief symptom -directe d physica l examination will be conducted as needed on Day 0 and prior to 
discharge on Day 3. 
c. Review of results are r equired prior to dosing on Visit 2 (ie, Naloxone Challenge).  
d. For confirmation of postmenopausal status only . 
e. Must be reviewed and confirmed as negative prior to dosing on Day 0.  
f. Includes pulse  rate, systolic and diastolic blood pressures.   Temperature (orally or with a temporal infrared scanner) will be measured at Screening and upon admission on 
Day [ADDRESS_1090725] 5 minutes in a sitting position.  
g. Vital signs will be recorded a t pre-dose (first naloxone dose) and at [ADDRESS_1090726] 10 minutes in a supi[INVESTIGATOR_2547].  
i. Continuous cardiac telemetry (heart rate, cardiac rhythm,  and oxygen saturation) will be monitored for approximately [ADDRESS_1090727] -dose or longer at the  discretion of the 
clinical research unit.  
j. Naloxone (0.2 mg IV) is administered first.  If there are no signs of withdrawal apparent within 30 seconds after admin istration, another 0.6 mg naloxone IV is administered.  
k. Include VASs for Drug Liking, High, Sleepy, Dizzy, Nausea, and Feel Sick.   K(a) Only  VASs for High, Sleepy, Dizzy, Nausea, and Feel Sick are administered at pre -dose.  
l. COWS is collected and recorded at pre-dose, and at [ADDRESS_1090728] naloxone dose and 5 minutes after the second dose is administered.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 13  
 m. Assessed throughout and collected using open -ended questions.  Symptoms of withdrawal following naloxone administration (Naloxone Challenge P hase)  will not be 
collected as adverse events unless they meet the criteria for an SAE.  Adverse events and s erious AEs will be collect ed from the time the informed consent is signed  through 
and including [ADDRESS_1090729]. 
*      C-SSRS Baseline/Screening Version will be used at the  screening Visit [ADDRESS_1090730] Visit Version  will be used . 
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 14  
 Table 2. Schedule of Activities for the Treatment Phase  
Study  Day Visits 3 to 8 
Treatment Phase  
Periods 1 to 6a 
 Follow -up Early 
termination/  
discontinuation 
(DC)  
Day -[ADDRESS_1090731] Dose   Pre-
dose  0 0.25 0.5 1 1.5 2 2.5 3 3.5 4 6 8 12 24 36 48   
CRU admission  X -> -> -> -> -> -> -> -> -> -> -> -> -> -> -> -> ->   
Medical history update  X                  X  
Continuing eligibility checkb X                    
Concomitant medication  X X -> -> -> -> -> -> -> -> -> -> -> -> -> -> -> -> X X 
Physical examinationc X                 Xm  X 
Safety laboratory testsd X                 Xm  X 
Urine drug testinge X                    
Serum pregnancy test (WOCBP only)                  Xm  X 
Urine pregnancy test (WOCBP only)f X                    
Contraception check  X                  X X 
Alcohol breathalyzer  or urine  X                    
Vital signsg X X  X X X X X X X X X X X X X X X  X 
Pulse oximetry , SpO 2  X → → → → → → → → → → → X X X    X 
Respi[INVESTIGATOR_697]   X → → → → → → → → → → → X X X     
Tidal volume   X → -> → → → → → → → → → X X X     
End-tidal ca rbon dioxide   X → -> → → → → → → → → → X X X     
Randomization   Xh                   
Pharmacodynamic (instrument) 
training /practice session  X                    
12-lead Electrocardiogramo X                 X  X 
Cardiac telemetryi  X → → → → → → → → → → → X       
Pupi[INVESTIGATOR_115726]   X  X X X X X X X X X  X X X X X  X 
Study treatment administration    X                  
VASj   Xj(a)  X X X X X X X X X X X X X X X  X 
VAS for Good Drug Effect, Bad Drug 
Effect, and Any Drug Effect     X X X X X X X X X X X X X X X   
“Overall  Drug Liking ” and 
“Take Drug Again ” VAS                 X X X  X  
Upjohn  Prep D1 Banked biospecimenk X                    
Pharmaco kinetic blood sampling   X  X X X X X X X X X X X X X X X  X 
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 15  
 a. Treatment Periods will  be separated by a minimum of 4 days between dosing.   
b. Continuing eligibility checks will include checks of urine drug screening ( UDS ), ethanol breath test, pregnancy tests, compliance with Lifestyle guideline s, and any changes 
to medical conditions that may require participant  rescheduling or discontinuation.  
c. Physical examinations will be brief and symptom -directed (if a change in medical history is reported).  Symptom -direc ted physical examinations may be  performed at 
admission to each visit at the discretion of the Investigator.   A complete physical examination will be conducted at End of Study  (EoS) or early termination (ET) .   
d. See Appendix [ADDRESS_1090732] will be obtained at the End  of Study 
Visit.  
g. Vital signs (including pulse  rate, systolic and diastolic blood pressures are measured at the nominal time points (±10 minutes)  after a resting period of at least 5 minutes in a 
sitting position.  Temperature (orally or with a temporal infr ared scanner) will be measured on Day -1 of each Treatment Visit only.  
h. Pre-dose or Day -1 for Visit 3  only.  
i. Continuous cardiac telemetry (heart rate, cardiac rhythm, and oxygen saturation) will be monitored from pre -dose for approximately [ADDRESS_1090733] -dose or longer at the 
discretion of the clinical research unit.  
j. Include VASs for Drug Liking, High, Sleepy, Dizz y, Nausea, and Feel Sick  measured at the nominal time points (±5 minutes) .  J(a).  Only VASs for High, Sleepy, Dizzy, 
Nausea, and Feel Sick are admi nistered at pre -dose.  
k. Visit [ADDRESS_1090734] at the next available time point when biospecimens are being collected in 
conjunction with a participant visit.  
l. Spontaneous AE reporting wil l occur throughout study; however, AEs will also be elicited using non -leading questions dur ing the Treatment Phase at pre -dose and at 0.0, 
0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, [ADDRESS_1090735] 10 minutes in a supi[INVESTIGATOR_2547].  
*      C-SSRS Since Last Visit Version  will be used  for all the visits  
 Serious and non -serious a dverse event 
monitoringl X X -> -> -> -> -> -> -> -> -> ->  -> -> -> -> -> -> X X 
Columbia Suicide -Severity Rating 
Scale* X                 X X X 
Discharge from CR U                  X   
Discharge from Stu dy                   X  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 16  
 2. INTRODUCTION  
2.1. Study Rationale  
Neurontin® (gabapentin) is indicated for postherpetic neuralgia in adults, adjunctive therapy 
in the treatment of partial onset seizures, with and without secondary generalization in adults 
and pediatric patients 3 years and ol der with epi[INVESTIGATOR_002].  
Gabapentin does not exhi bit affinity for benzodiazepi[INVESTIGATOR_050], opi[INVESTIGATOR_2573] (mu, delta or kappa), or 
cannabinoid 1 receptor sites; however, gabapentin misuse and abuse  has been reported at 
increasing rates .  Individuals abusing gabapentin describe e xperiences such as euphoria, 
improved socia bility, relaxation and a marijuana -like “high”.1-[ADDRESS_1090736] abuse potential, particularly 
among individuals with  a history of opi[INVESTIGATOR_2554].  Gabapentin abuse is reported both alone 
(ie, without other drugs), and in conjunction with opi[INVESTIGATOR_483240] ‘high’ obtained from 
opi[INVESTIGATOR_2438].1-[ADDRESS_1090737] -authorization safety study (PASS) to  evalua te 
gabapentin in combination with a moderate dose  of oxycodone hydrochloride  (HCl) 
compared to oxycodone HCl monotherapy and placebo in healthy non -drug dependent , 
recreational drug users . 
2.2. Background  
The precise mechanisms by [CONTACT_791269][INVESTIGATOR_591791].  Gabapentin is structurally related to the neurotransmitter gamma -aminobutyric 
acid (GABA) but has no effect on GABA binding, uptake, or degradation.   In vitro studies 
have shown that gabapentin binds with high-affinity to the α2δ subunit of voltage -activated 
calcium cha nnels; however, the relationship of gabapentin binding to its therapeutic effects  
or potential abuse is unknown.   
Approximately 1.1% of the general population and 22% of those attending addic tion 
facilities have a history of abuse of gabapentin8,[ADDRESS_1090738] been deaths from  gabapentin 
use with benzodiazepi[INVESTIGATOR_199721].1-7  The purpose of the present study is to assess 
prospectively the abuse potential of gabapentin when used concomitantly with oxycodone.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 17  
 2.2.1.  Clinical Overview  
Neurontin® formulations  are available i n capsule strengths of 100 mg, 300 mg  and 400  mg, 
tablets of 600 mg and 800 mg, and in an oral solution containing  250 mg/5 mL of 
gabapentin .  Gabapentin is rapi[INVESTIGATOR_24584] .  Following oral administration  of these dosag e 
forms, p eak conc entrations were obser ved within 2 to 3 hours .  Gabapentin bioavailability is 
not dose proportional; i e, as dose is increased, bioavailability decreases.  Bioavailability of 
gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 
3600, and 4800 mg/day  given in [ADDRESS_1090739] 
on the rate and extent of absorption of gabapentin (14% increase in area under the curve 
(AUC ) and maximum observed  concentration ( Cmax).  Gabapentin is not appreciably 
metabolized in humans.  Gabapentin is eliminated from the systemic circulation by [CONTACT_791270].  Gabapentin elimination half -life is 5 to 7 hours and is 
unaltered by [CONTACT_791271].  Gabapentin elimination rate constant, 
plasma cle arance, and renal clearance are directly proportional to creatinine clearance.10 
In vitro studies did not  show  inhibition of any cytochrome P450 (CYP) isozymes by 
[CONTACT_791272].   However, it is reported in the literature that 
when a 60 -mg controlled -release morphine capsule was administered 2 hours prior to a 
600-mg Neuronti n capsule (N=12), mean gabapentin AUC increased by 44% compared to 
gabapentin administered without morphine .  Morphine pharmacokinetic parameter values 
were not affected by [CONTACT_791273] 2 hours after morphine.   The magnitude of 
interaction a t other doses is not known.11  
The immediate -release (IR) oral formulation of oxycodone HCl is indicated for the 
management of moderate to severe pain where the use of an opi[INVESTIGATOR_791231].   
Oxycodone is a  µ-agonist opi[INVESTIGATOR_791232] a Schedule II drug.  Like other 
opi[INVESTIGATOR_791233] a, it can be abused and is subject to criminal diversion.  About 
60% to 87% of an oral dose of oxycodone HCl reaches the systemic circulation.  Oxycodone 
dose proportionality has been established.  A single 30  mg oral dose of oxycodone tablet 
reaches  peak  concentration ( Tmax) in 2.6 ±3 hours and has a t½ of 3.85 ±1.3 hours.  A sin gle 
10 mg dose of oxycodone oral solution under fasted condition reaches Tmax in 
1.25 ±0.5 hours.12  Oxycodone is extensively metabolize d in the liver via CYP3A4/5 to 
noroxycodone (45%) and via CYP2D6  to oxymorphone (19%) .  Both noroxycodone and 
oxymorphone are further metaboli zed to noroxym orphone.  Noroxycodone exhibits only 
weak antinociceptive potency; its affinity for µ -opi[INVESTIGATOR_791234].  Although oxymorphone and noroxymorphone have higher affinity 
for µ -opi[INVESTIGATOR_791235] , neither of them can 
readily cross the blood –brain barrier (BBB) and, thu s their contribution s to analgesia effect 
following oxycodone administration is thought to be cl inically insignificant.  The elimination 
half-life of oxycodone has been reported to be approximately 3 -5 hours .12  Due to 
CYP -mediated metabolism, oxycodone is prone to drug interactions such as conco mitant  
administration with either CYP3A inhibitors/inducers or CYP2D6 inhibitors or both.  
Oxycodone, as well as other opi[INVESTIGATOR_2467], may enhance the neuromuscular blo cking 
action of skeletal muscle relaxants and produce an increased degree of respi[INVESTIGATOR_791236].  Oxycodone produces  respi[INVESTIGATOR_791237]-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 18  
 respi[INVESTIGATOR_791238].  The respi[INVESTIGATOR_791239] a reduction in the  
responsiveness of the brain stem respi[INVESTIGATOR_791240].  
2.3. Benefit/Risk Assessment  
Neurontin® and oxycodone HCl are not expected to provide any clinical benefit to healthy 
participants  in thi s study .  This study is designed to assess the abuse potential of Neurontin® 
when taken orally alone and concomitantly with oxycodone HCl in healthy non -drug 
dependent, recreational opi[INVESTIGATOR_45157] . 
More detailed information about the known and expected benef its and risks and reasonably  
expected adverse events (AEs) of gabapentin® and oxycodone HCl may be found in the  
package insert s, which are the single reference safety document s (SRSD) for this study.   The 
SRSD for Neurontin® and oxycodone  HCl is their resp ective Product Insert.10,13 
3. OBJECTIVES AND ENDPOINTS  
Objectives  Endpoints  
Primary :  Primary :  
• To determine the abuse potential of orally 
administered Neurontin® taken  concomitantly  
with oxycodone  HCl in non -dependent , 
recreational opi[INVESTIGATOR_791241] . • Bipolar visual analogue scale ( VAS ) for “Drug 
liking ” [maximum effect ( Emax)]. 
Secondary:   Secondary :  
• To evaluate additional pharmacodynamic ( PD) 
effec t, pharmacokinetic ( PK) and safety of 
Neurontin® when used alone and concomitantly 
with oxycodone  HCl in non -dependent, 
recreational opi[INVESTIGATOR_791242].   Pharmacodynamic Endpoints : 
• Bipolar VAS for “Drug liking ” [time for E max 
(TE max), area under the effect -time profile 
from time zero to the last quantifiable effect  
(AUEC last), and partial AUEC s (AUEC 1, 
AUEC 2, AUEC 3, AUEC 4, AUEC 8)]. 
• Unipolar VAS for “High ” (Emax, TE max and 
AUEC last), and partial AUEC (AUEC 1, 
AUEC 2, AUEC 3, AUEC 4, AUEC 8). 
• Bipo lar VAS for “Take Drug Again ” at 24, 
[ADDRESS_1090740] dose . 
• Bipolar VAS for “Overall Drug Liking ” at 24, 
[ADDRESS_1090741] dose. 
• Unipolar VAS for “Good Drug Effect” .   
• Unipolar VAS for “Bad Drug Effect” .  
• Unipolar VAS for “Any Drug Effect” .  
• Pupil s ize (diameter) . 
Pharmacokinetic Endpoints : 
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 19  
 Objectives  Endpoints  
• Cmax, Tmax, area under the plasma 
concentration -time profile from time zero to 
the time of the  last quantifiable concentration  
(AUC last) of gabapentin  and oxycodone . 
• Area under the plasma concentration -time 
profil e from time zero extrapolated to infinity 
time (AUC inf) and half -life (t½), if data 
permits, of gabapentin  and oxycodone.  
• Partial  AUC s (AUC 1, AUC 2, AUC 3, AUC 4, 
AUC 8) of gabapentin and oxycodone.  
Safety  endpoints : 
• Vital signs [blood pressure ( BP), pulse  rate 
(PR)]. 
• Respi[INVESTIGATOR_697] (RR) . 
• oxygen saturation  of hemoglobin (SpO 2). 
• Physical examination . 
• 12-lead electrocardiogram ( ECG ). 
• Clinical Lab and adverse events (AEs) . 
Tertiary/ Exploratory : Tertiary/ Exploratory : 
Exposure -response relationship between gaba pentin 
concentration and selected PD effect in the presence 
and absence of oxycodone . Correlation  between gabapentin concentrations and 
select ed PD endpoints ( bipolar VAS for “ Drug 
Liking ”, Unipolar VAS for “H igh”, pupil diameter ) in 
the presence and absen ce of oxycodone, as data permit.  
• To enable exploratory research through 
collection of banked biospecimens, unless 
prohibited by [CONTACT_168038].  • Potential results from exploratory analysis of 
banke d biospecimens (these resu lts may or may 
not be generated in the context of the present 
study).  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 20  
 4. STUDY DESIGN  
4.1. Overall Design  
This will be a randomized, double -blind, double -dummy, placeb o- and active -controlled, 
6-treatment, 6-period crossover single -dose, Williams square design  study in healthy male 
and/or female  adult, non-drug-dependent recreational opi[INVESTIGATOR_45157] .  The study includes 
Screening, a Qualification Phase, a Treatment Phase and Follow -up.  This study will 
randomize approximately 60 adult male and female (at least 20% fe males)  participant s 
(10 participants in each sequence) in the Treatment Phase  to ensure  at least 48 participant s 
complete the Treatment Phase of the study.   Dropouts for non -safety reasons in the 
Treatment Phase may be replaced at the discretion of the Investigator in consultation with the 
Sponsor . 
The following study visits  are required , see Figure 1 and the SoA (Table 1 and Table 2): 
• Visit 1, Screening  will occur within 28 days pri or to Visit 2 . 
• Visit 2, Qualification  Phase will require inpatient stay at the clinical research unit 
(CRU ) for 3 nights : 
• Naloxone Challenge P hase, Day 0. 
• Drug Discrim ination , Days 1 and 2  will require inpatient stay at the CRU for 
2 nights . 
• End of Drug Di scrimination requires an i npatient stay at the CRU overnight to 
ensure discharge occurs 24 hours after receiving oxycodone or placebo.   
• Participant will proceed to Visit [ADDRESS_1090742] dose of study inte rvention during Qualificat ion Phase. 
• Visits 3 to 8 , Treatment Phase  will require a total of 18 overnight inpatient stays at 
the CRU : 
• Each visit will require an inpatient stay at the CRU of 3 nights .  
• Each visit will be separated by a washout period of at least 4 days.  Washout 
period is calculated between two subsequent study drug administra tions.  
• End of Study assessments will be at the CRU and occur [ADDRESS_1090743] study 
drug dosing  of period 6 or at the time of early withdrawal . 
• For the entire stu dy, 21 overnight inpatient stays will be required.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 21  
 4.1.1.  Screening  
As shown in the S oA (Table 1), all participant s will complete a Screening Visit with a 
standard medical screening to  determine eligibility for this study.   This visit (Visit 1) will 
occur within [ADDRESS_1090744] dose in Qualification  Phase of the study  (Visit 2) . 
4.1.2.  Qualification  Phase  (Visit 2; Days 0 to 3)  
[IP_ADDRESS].  Naloxone Challenge  (Day 0)  
Eligible participant s who successfully complete the Screening  Visit will return to the s tudy 
center to complete the Naloxone Challenge.  The Naloxone Challenge (Day 0) will be  
performed to ensure the participant  is not physically dependent on opi[INVESTIGATOR_2438].  
During the Naloxone Challenge, all participants will recei ve intravenous (IV) naloxone  
0.[ADDRESS_1090745] signs and symptoms of opi[INVESTIGATOR_43351], as assessed by [CONTACT_791274][INVESTIGATOR_9721] (COWS score <5), (Appendix 8 ) will be eligible  to 
proceed to the Drug Discrimination Phase . 
Any participant demonstrating evidence of withdrawal (COWS score ≥5) on any assessment 
will not be eligible for further participation in the trial.  The participant  will be released from 
the study center when medically stable, as determined by [CONTACT_093].  Symptoms 
reported in the COWS as a consequence of opi[INVESTIGATOR_791243] a new AE or serious adverse event (SAE) . 
[IP_ADDRESS].  Instrument T raining  
After successful completion of the Naloxone Challenge, all eligible parti cipants will undergo 
training on proper completion of the instruments (VAS) used to collect the PD endpoints.  
This will be done to ensure that participant s fully understand how to perform the tests, that 
they feel comfortable with the testing methods used  for PD assessment and  have attained a 
stable level of performance on the va rious performance -based measures.   Detailed 
instructions for participant  training will be provided in a separate study specific document.  
[IP_ADDRESS].  Drug Discrim ination  (Days 1 to 3)  
Followin g completion of the  instrument training , the eli gible participates will be e valuated 
for drug discrimination .  The purpose of this phase is to select participants who report drug 
liking in response to a positive control and demonstrate a meaningfully diffe rent response 
from that produced by [CONTACT_14296].  
The drug discrimination will be performed over 2 consecutive days.   The treatments will be 
double  blind.  The participants will be randomly assigned to receive one of the blinded 
treatments  (oxycodone 20 mg or placebo) on the first day and then receive the alternate 
treatment the next day according to a Williams square design  (Table  3).  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 22  
 Table  3. Schema for Qualification Phase  
Treatment Periods 1 and 2  
Day 1  Day 2 
A B 
B A 
Treatment A: oxycodone HCl 20 mg.  
Treatment B: placebo.  
 
Pharmacodynamic  (VAS) , pupi[INVESTIGATOR_791244] (vital signs, pulse oximetry 
and respi[INVESTIGATOR_697]) will be c onducted at pre -dose and up to [ADDRESS_1090746] dosing.  Continuing 
eligibility will be based on the participant ’s ability to:  
• A placebo resp onse between 40 -60 points on a bipolar “Drug Liking ” Emax VAS of 
0-100. 
• The positive control should produce a score outside of the placebo range , and should 
be at least 15 points great er than the placebo response .  
• Tolerate study treatments safely ; ie, SpO 2 ≥90%, no epi[INVESTIGATOR_791245] [ADDRESS_1090747] -dose. 
• Demonstrate general behavior suggestive that the participant could successfully 
complete  the study, as judged by [CONTACT_791275] . 
Only those participants who produce these results may be enrolled in the study.  
Participants will be dis charged from t he clinic on Day [ADDRESS_1090748]  dose of either oxycodone or placebo.  
Following completion of Day 2 procedures, the study data for each participant  will be 
unblinded and a determination will be made  by [CONTACT_403000] (and/or 
designee) if the participant  is eligible to continue in the study.  
4.1.3.  Treatme nt Phase  (Visits 3 to 8) 
Participant s who successfully complete the Naloxone Challenge and the Drug Discrimination 
Phase and who meet all the Randomization Criteria will be randomized into the Treatment 
Phase  of this randomized, double -blinded, placebo - and active -controlled, crossover study . 
On Day [ADDRESS_1090749] 4 days, 
participant s will receive a n oral  dose of either gabapentin  600 mg  or 1200 mg alone , or 
concomitantly  with a 20 mg  dose of oxy codone  HCl or 20 mg  monother apy of oxycodone 
HCl or a placebo .  Study treatments will be administered under fasted conditions (overnight 
fast and no food until 4 hours after dosing).  Water will be allowed without restriction until 
1 hour prior to dosing a nd 1 hour after dos ing. 
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 23  
 Physiological and subjective scales will be used to assess the abuse potential of each study 
treatment, right before each blood sample  collection  for the analysis of plasma gabapentin  
and oxycodone  concentrations at  pre-dose ( within  30 minutes  prior t o dosing) and post -dose 
as outlined in the SoA ( Table 2).  Vital signs including respi[INVESTIGATOR_2842], pulse oximetry  and 
pupi[INVESTIGATOR_791246].  
4.2. Scientific Ratio nale for  Study Design  
There is a need to systematically evaluate the abuse potential of gabapentin taken 
concomitantly with an opi[INVESTIGATOR_2480], such as oxycodone, investigating a range of  gabapentin dose 
(the highest  therapeutic and supra -therapeutic) combined with the opi[INVESTIGATOR_791247] -drug 
dependent population with drug abuse experience.   Therefore, this clinical trial will evaluate 
the gabapentin/opi[INVESTIGATOR_791248] a cross -over design with comparison to pla cebo, 
gabapen tin alone, and a moderate dose of the opi[INVESTIGATOR_791249] a positive control.   Hence 
the study design will employ a 6 -sequence, 6 -period, cross -over design which will include 
the placebo, a positive control  (oxycodone 20 mg) , two doses of ga bapentin alon e (600 mg 
and 1200 mg) and each gabapentin dose in combination with [ADDRESS_1090750] 
4 days minimizing the  carry over effects of the treatmen ts, especiall y if additive or 
synergistic effects are noted with the combination treatments.   Pharmacokinetic s will be 
evaluated to allow for an exploratory correlation of pharmacodynamic effects . 
Banked biospecimens will be collected for exploratory  
pharm acogenomic/ge nomic/biomarker analyses and retained in the Biospecimen Banking 
System (BBS), which makes it possible to better understand the investigational product’s 
mechanism of action and to seek explanations for differences in, for example, exposure, 
tolerability, safety, and/or efficacy not anticipated prior to the beginning of the study.  
4.3. Justification for Dose  
The highest therapeutic dose of Neurontin® in adults for postherpetic neuralgia is 600  mg, 
three times a day (t.i.d) (1800 mg/day).  Doses abov e 1800 mg/day  did not demonstrate 
additional clinical  benefit.  The recommended maintenance dose of Neurontin® for epi[INVESTIGATOR_591795] [ADDRESS_1090751] therapeutic single dose 
for both indications.  According to the US Food and  Drug Administration ( FDA ) guidance 
for assessment of abuse potential  of drugs ,[ADDRESS_1090752] proposed therapeutic  dose are 
included in the study to compare to a positive control and placebo.  As such , 600 mg and 
1200 mg gabapentin (2x of the highest therapeutic dose) are selected in this study to 
determine the abuse potential of Neurontin® when administered concomitantly w ith 
oxycodone  HCl [ADDRESS_1090753]  of gabapentin to oxycodone.  Based on  published studies, the reported mean “Drug 
Liking” bipolar V AS Emax scores for a [ADDRESS_1090754] completed the study if  he/she has completed all phases of  
the study including the last scheduled procedure shown in the SoA. 
The end of the study is defined as the date of the last visit of the last participant in the study . 
5. STUDY POPULATION  
This study can fulfill its objectives only if ap propriate participant s are enrolled.  The 
following eligibility criteria are designed to select participant s for whom participation in the 
study is considered appropriate.  All relevant medical and nonmedical  conditions should be 
taken into consideration w hen deciding whether a participant  is suitable for this protocol .  
Prospective approval of protocol deviations to recruitment and enrollment criteria , also 
known as protocol waivers or exemptions, is not perm itted. 
5.1. Inclusion Criteria  
Participants are eligi ble to be included in the study only if all the following criteria apply:  
Age and Sex : 
1. Male and female p articipant s must be [ADDRESS_1090755]  be no less than 20% participants in the Treatment Phase.   
Refer to Appendix  4 for reproductive criteria for male ( Section 10.4.1 ) and female 
(Section 10.4.2 ) participants.  
Type of Participant and Disease Characteristics:  
2. Male and female p articipants who are overtly healthy .  Healthy is defined as no 
clinically relevant abnormalities identified by a detailed medical history, complete  
physical examinati on, vital signs, 12 -lead ECG, and/or clinical laboratory tests.   
3. Participants must have drug abuse experience with opi[INVESTIGATOR_2438]; ie, must have  used 
opi[INVESTIGATOR_378551] -therapeutic purposes (ie, for psychoactive  effects) on at least 
[ADDRESS_1090756] once in the 8 weeks befor e the Screening 
Visit (Visit 1).  
4. Participants must satisfactorily complete both the Naloxone Challenge and the Drug 
Discrimination.  
5. Participants who are willing and able to comply with all scheduled visits, treatment 
plan, laboratory tests , lifestyle considerations, and other study procedures.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 25  
 Weight:  
6. Body mass index (BMI) of 17.5 to 34 kg/m2, inclusive ; and a total body weight 
≥50 kg (110  lb).  
Informed C onsent:  
7. Capable of giving signed informed consent as described in Appendix 1 , which 
includes compliance with the requirements and restrictions listed in the informed 
consent document  (ICD) and in this protocol.  
5.2. Exclusion Criteria  
Participants are excluded from the study if any of the following criteria apply:  
Medical Conditions:  
1. Current  or past  diagnosis  of any type of drug dependence  within  the past year.   
Diagnosis of substance and/or  alcohol dependence (excluding caffeine and nicotine)  
will be assessed by [CONTACT_791276] -IV (DSM -IV) criteria performed at Screening.   Current  drug use 
will be allowed  if the candidate  can produce  a negative  urine  sample  and are free of 
any signs/symptoms  of withdrawal.   The candid ate will be informed if they have a 
positive breathalyzer test.  
2. Evidence or history of clinically significant hematological, renal, endocrine, 
pulmonary, gastrointe stinal, cardiovascular, hepatic, psychiatric, neurologic al, or 
allergic disease (including drug allergies, but excluding untreat ed, asymptomatic, 
seasonal allergies at the time of dosing ). 
3. Any condition possibly affecting drug absorption (eg, gastrectomy)  excluding 
cholecystectomy within 1 year prior to study . 
4. Abnormal baseline EtCO 2 <35mm Hg or >45 mm Hg.  
5. Clinical or laboratory evidence of active hepatitis A infection or a history of  human 
immunodeficiency virus (HIV) infection, hepatitis  B, or hepatitis  C, and/or  positive 
testing for HIV, hepatitis  B surface antigen (HBsAg), hepatitis B core antibody 
(HBcAb ), or hepat itis C antibody (HCVAb ).   
6. Participant s with active suicidal ideation or suicidal behavior within 5 years prior to 
Screening as determined th rough the use of the Columbia -Suicide Severity Rating 
Scale  (C-SSRS)  or active ideation identified at Screening or on Day  0.  
7. Participant s with any history of sleep apnea, myasthenia  gravis  or glaucoma.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 26  
 8. Other acute or chronic medical or psychiatric condit ion including recent (within the 
past year) or active suicidal ideat ion or behavior or laboratory abnormality that may 
increase the risk associated with study participation or investigational product 
administration or may interfere with the interpretation of study results and, in the 
judgment of the investigator, would mak e the participant inappropriate for entry into 
this study.  
Prior/Concomitant Therapy:  
9. Use of prescription or nonprescription drugs and dietary  supplements within 7  days or 
5 half-lives (wh ichever is longer) prior to the first dose of investigational produc t.  
(Refer to Section 6.5 for additional details ). 
10. Herbal supplements  and herbal medications must be discontinued at least [ADDRESS_1090757] dose of study medication.  
Prior/Con current Clinical Study Experience:  
11. Previous administration  with an investigational drug within 30  days (or as determined 
by [CONTACT_19970]) or 5 half-lives (whichever is longer) preceding the first dose 
of investigational product used in this study . 
Diagnostic Assessments:  
12. Positive urine drug screen (UDS) for substances of abuse at each admission in 
Qualification and Treatment Phase, excluding tetrahydrocannabinol (THC).   If a 
participant prese nts with a positive UDS excluding THC at any admission  or any 
visit, the investigator, at his/her di scretion, may reschedule  a repeat of UDS until the 
UDS is negative, excluding THC, before the participate is permitted to participate  in 
any phase of the st udy.  
13. Unable to abstain from using THC during the Q ualification and Treatment Phase of 
the study.  
14. Has participated in, is currently participating in, or is seeking treatment for 
substance -and/or alcohol -related disorders (excluding nicotine and caffeine).  
15. Has a  positive alcohol breathalyzer  or urine  test at each admission to the study center 
during Qualification and Treatment Phases .  Positive results may be repeated and/or 
participant s re-scheduled at the Investigator’s discretion s.  
16. Participants are heav y smokers or users of other types of nicotine products (>20 
cigarettes equivalents per day) .  
17. Participants are unable to abstain from smoking for at least [ADDRESS_1090758] 
8 hours after study drug administration.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 27  
 18. Screening sitting blood pressure  (BP) 140 mm Hg (systolic) or 90 mm Hg 
(diastolic), following at least [ADDRESS_1090759].  If BP is 140 mm Hg (systolic) or 
90 mm Hg (diastolic), the BP should b e repeated 2 more times and the average of 
the 3 BP values should be used to determine the participant ’s eligibility.   Repeated 
BP tests should be spaced at least 5 minutes  apart.  
19. Baseline (screening)  12-lead electrocardiogram ( ECG ) that demonstrates  clinically  
relevant abnormalities that may affect participant  safety  or interpretation of study  
results (eg,  baseline corrected QT ( QTc) interval as determined by [CONTACT_791277]  (QTcF) >450 ms ec, complete left bundle branch block [ LBBB ], signs of an 
acute or indeterminate -age myocardial  infarction, ST -T interval changes suggestive of 
myocardial i schemia, second - or third -degree  atrioventricular [AV] block, or serious 
bradyarrhythmias or tachyarrhythmias).  If the baseline uncorrecte d QT  interval  is 
>450  msec, this interval should be rate -corrected using the Fridericia method and the 
resulting QTcF  should be used for decision making and reporting.   If QTc F exceeds 
450 msec, or QRS exceeds 120  msec, the ECG should be repeated 2  more ti mes and 
the average of the 3  QTcF or QRS values should be used to determine the 
participant’s eligibility.   Computer -interpreted ECGs should be overread by a 
physician experienced in reading ECGs before excluding participant s. 
20. Participant s with ANY  of the following abnormalities in clinical laboratory tests at 
screening, as assessed by [CONTACT_1758] -specific laboratory and c onfirmed by a single 
repeat  test, if deemed necessary : 
• Aspartate aminotransferase  (AST) or alanine aminotransferase  (ALT) level 
1.5 × upper limit of normal  (ULN);  
• Total bilirubin level 1.5 × ULN; participants with a history of Gilbert's 
syndrome may have  direct bilirubin measured and would be eligible for this study 
provided the direct bilirubin level is  ULN.  
Other Exclusions:  
21. Blood donation  (excluding plasma donations) of approximately 1  pi[INVESTIGATOR_11731] (500  mL) or 
more  within [ADDRESS_1090760] 
of the study.   
5.3. Lifestyle Considerations  
The following guidelines are provided:  
5.3.1.  Meals and Dietary Restrictions  
• Participant s must abstain from all food and drink (except water) at least [ADDRESS_1090761]  10 hours prior to the collection of the 
pre-dose pharmacokinetic  (PK) sample  for fasted trea tment . 
• Water is permitted until [ADDRESS_1090762] administration .  Water 
may be consumed without restriction beginning 1  hour after dosing.  Noncaffeinated 
drinks (except grapefruit or grapefruit -related citrus fruit juices —see below) may be 
consumed with meals and the e vening snack . 
• Lunch will be provided approximately 4  hours after dosing . 
• Dinner wi ll be provided approximately 9  to 10  hours after dosing . 
• An evening snack may be permitted . 
• Participants will refrain from consuming red wine, grapefruit , or grapefruit -related 
citrus fruits (eg, Seville oranges, pomelos, fruit juices) from [ADDRESS_1090763] until collection  of the final PK blood sample.  
• While participants are confined, the ir total daily nutritional composition should be 
approximately 55% carbohydrate, 30% fat , and 15%  protein.  The daily caloric inta ke 
per participant  should not exceed approximately 3200  kcal.  
5.3.2.  Caffeine, Alcohol, and Tobacco  
• Participants will abstain from caffeine -containing products for 24  hours prior to the 
start of dosing until collection of the final PK sample of each study period.  
• Participants will abstain from alcohol for 24  hours prior to admission to the clinical 
research unit (CRU) and continue abs taining from alcohol until collection of the final 
PK sample of each study period.  Participants may undergo an alcohol breath test or 
blood alcohol test at the discretion of the investigator.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 29  
 • Participants will not be permitted to smoke from at least [ADDRESS_1090764] 
8 hours after  dosing in the Qualification and Treatment Phases.  At all other times 
while housed in the stu dy center smoking may be permitted in short breaks at the 
study center staff’s discretion.  The use of oral or chewed tobacc o and/or nicotine -
containing products (including topi[INVESTIGATOR_113040]) is not permitted from at least [ADDRESS_1090765] 8 hours  after study drug administration .  
5.3.3.  Activity  
• Participants will abstain from strenuous exercise (eg, heavy lifting, weight tra ining, 
calisthenics, aerobics) for at least 48  hours prior to each blood collection for clinical 
laboratory tests.  Walking at a nor mal pace will be permitted . 
5.3.4.  Contraception  
The investigator or his or her designee, in consultation with the participant, wi ll confirm that 
the participant has selected an appropriate method of contraception for the individual 
participant and his or her pa rtner(s)  from the permitted list of contraception methods (see 
Appendix  4) and will confirm that the participant has been instructed in its consistent and 
correct use.  At time points indicated in the  Schedule of Activities  (SoA) , the investigator or 
designee w ill inform the participant of the need to use highly effective contraception 
consistently and correctly and document the conversation and the participant’s affirmation in 
the participant’s chart (participants need to affirm their consistent and correct use  of at least 
1 of the selected methods of contraception).  In addition, the investigator or designee will 
instruct the participant to call immediately if the selected contraception method i s 
discontinued or if pregnancy is known or suspected in the partici pant or partner.  
5.4. Screen Failures  
Screen failures are defined as participants who consent to participate in the clinical study but 
are not subsequently entered in the Qualification Phase.  Screen failure data are collected and 
remain as source and are not r eported to the clinical database.  
6. STUDY INTERVENTION  
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study participant according to 
the study protocol . 
For the purposes of this protocol, the term investigational product m ay be used 
synonymously with study intervention.  
6.1. Study Intervention s Administered  
For this study, the investigational product s are Neurontin® and oxycodone  HCl.  
Neurontin® and oxycodone will be provided by [CONTACT_791278] [ADDRESS_1090766]  at approximately 08 :00 hours (plus  or minus 2  hours).  Detailed instructions on 
preparation of all study treatments, including steps to maint ain the double blind, will be 
provided separately  in Drug Adminis tration Instruction  (DAI) .   
In order to standardize the conditions on PK sampling d ays, all participant s will be required 
to refr ain from lying down (except when required for BP, pulse rate , and ECG 
measurements), eating, and drinking beverages other than water during at least  the first 
[ADDRESS_1090767]  1 hour following dosing.  
6.2. Preparation/H andling/Storage/Accountability  
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study intervention s received and any 
discrepancies are rep orted and resolved before use of the study int ervention , as 
applicable for temperature -monitored shipments .  
2. Only participants enrolled in the study may receive study intervention and only 
authorized site staff may supply or administer study intervention.   All study 
interventions must be stored in a secure, environmentally controlled, and monitored 
(manual or automated recording) area in accordance with the labeled storage  
conditions with access limited to the investigator and authorized site staff.  At a 
minimum, daily minimum and maximum temperature s for all site storage locations 
must be documented and available upon request.  Data for nonworking days must 
indicate the minimum and maximum temperature since previously documented for all 
site storage locati ons upon return to business . 
3. The investigator , institution, or the head of the medical institution (where applicable) 
is responsible for study intervention accountability, reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final dispo sition records).   All study 
intervention s will be accounted for using a n investigational product accountability 
form/record.  
4. Further guidance and information for the final disposition of unused study 
interventions are provided in the  investigational produc t (IP) manual.  
5. Any storage conditions stated in the SRSD will be superseded by [CONTACT_177264].  
6. Study interventions  should be stored in their original containers and in accordance 
with the labels.  
PF-[ADDRESS_1090768] be quarantined and not used until Sponsor  provides permission to use the study 
intervention.  It will not be considered a protocol deviation if Sponsor  approves the 
use of the study interven tion after the temperature  excursion.   Use of the study 
intervention  prior to Sponsor  approval will be considered a protocol 
deviation.  Specific details regarding the definition of an excursion and information 
the site should report for each excursion wil l be provided to the site in the IP manual . 
8. The sponsor or designee will provide guidance on the destruction of unused study 
intervention  (eg, at the site).  If destruction is authorized to take place at the 
investigator site, the investigator must ensure that the materials are des troyed in 
compliance with applicable environmental regulations, institutional policy, and any 
special instructions provided by [CONTACT_2728] , and all destruction must be adequately 
documented.  
6.2.1.  Preparation and Dispensing  
Within this prot ocol, preparation refers t o the investigator site activities performed to make 
the investigational product ready for administration or dispensing to the participant /caregiver  
by [CONTACT_3436].  Dispensing is defined as the provision of investigational pr oduct, 
concomitant treatme nts, and accompanying information by [CONTACT_22806](s) to a 
healthcare provider, participant , or caregiver  in accordance with this protocol.  Local health 
authority regulations or investigator site guidelines may use alter native terms for these 
activities.  
Investigational products will be prepared at the CRU in the individual dosing containers by 
[ADDRESS_1090769] 1 of whom is an appropriately qualified and experienced member of the 
study staff (eg , physician, nurse, ph ysician’s assistant, nurse practitioner, pharmacy 
assistant/technician, or pharmacist).  The investigational products will be provided in 
appropriate containers and labeled in accordance with Sponsor  regulations and the clinical 
site’s labeling requirement s.   
6.3. Measures to Minimize Bias: Randomization and Blinding  
6.3.1.  Allocation to Investigational Product  
At screening, participants  will be assigned a subject screening  Identifier number  (SSID) via 
an automated Interactive Response Technology  (IRT)  or equivalent s ystem.   
Following screening the participants will be random ly assigned a qualification randomization 
number (QRN)  via the IR T or equivalent system using a 1:1 randomization .  The QRN  will 
be retained throughout the study  and will correspond  to the blinded  qualification phase . 
After satisfactory completion of the qualification phase, participants will randomly be 
assigned a study randomization number ( SRN) via the IRT or equivalent sys tem using a 1:1 
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 32  
 randomization for the treatment phase.   The SRN will be re tained throughout the study and 
will correspond to the blinded treatment sequence.  
6.3.2.  Breaking the Blind  
The investigator site, study monitor(s), and Sponsor  personnel will be blinded t o study 
treatment.  The site will have an unblinded pharmacist for prepara tion of the study drugs.  
The unblinded pharmacist or unblinded designee at the study center  will be responsible for 
ensuring blinding procedure oversight at the study center, accord ing to the study center 
guidelines.  The unblinded pharmacist will not be able to perform any other duties for this 
study outside of the requirements of ensuring the blind.  
At the completion of the Drug Discrimination Phase, the Investigator and/or design ee will 
un-blind the participant ’s treatment sequence in order for the Inv estigator and Sponsor  
personnel  to assess participant  eligibility to continue to the Treatment Phase of the study.  
Additional information regarding the criteria for Drug Discrimination can be found in 
Section [IP_ADDRESS] .  Treatment data during the Trea tment Phase of the study will remain blinded 
throughout the course of treatment until the study database has been locked.  Unblinding 
during the Treatment Phase will not occur unless medically necessary  for participant  safety.  
The IRT will be programmed wi th blind -breaking instructions.   In case of an emergency, the 
investigator has the sole responsibility for determining if unblinding of a participant ’s 
treatment assignment is warranted.   Participant sa fety must always be the first consideration 
in making such a determination.   If the investigator decides that unblinding is warranted, the 
investigator should make every effort to contact [CONTACT_791279] a participant ’s treatment assignment unless this could delay further ma nagement 
of the participant.   If a participant ’s treatment assignment is unblinded, the sponsor must be 
notified within [ADDRESS_1090770] be recorded in the source documentation and data collection tool (DCT) . 
The study -specific IRT reference manual will provide the contact [CONTACT_110275].  
6.4. Study Intervention Compliance  
Investigational produc t will be administered under the supervision of investigator site 
personnel.  The oral cavity of each participant will be examined following dosing to ensure 
the investigational product was taken.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 33  
 6.5. Concomitant Therapy  
Use of prescription or nonprescription drugs and dietary  and herbal  supplements  are 
prohibited  within 7  days or 5  half-lives (whichever is longer) prior to the first dose of 
investigational product.  Limited use of nonprescription  medications  that are not believed to 
affect participant  safety o r the overall results of the  study may be permitted on a case-by-case 
basis following approval by [CONTACT_456] .   
Hormonal contraceptives that meet the requirements of this study are allowed to be used in 
participants who are WOCBP (see Appendix  4). 
All concomitant treatments taken during the study must be recorded with indication, daily 
dose, and start and stop dates of administration.  All participant s will be questioned about 
concomitant treatment at each clin ic visit.  
Treatments taken w ithin [ADDRESS_1090771] will be documented as concomitant treatments.  
6.6. Dose Modific ation  
Dose modification will  not be allowed in this single dose study.  
6.7. Emergency Intervention  
• The investigational site shall have a fully equipped “crash cart” and advanced cardiac 
life support (ACLS) certified staff present during the entire study.  
• Acute gabapentin and/or oxycodone  toxicity can be manifested as drowsiness, 
respi[INVESTIGATOR_2341], and somnolence progressing to stupor , coma  or death .  In the 
event that acute gabapentin and/or oxycodone  toxicity occurs, primary attention shall 
be given to re -establishment and/ or maintenance of an open  airway including assisted  
or controlled ventilation.   
• Other supportive measures  including the use of oxygen and vasopressors should be 
employed in the standard management of circulatory shock if it occurs in the  event of 
gabapent in and/or oxycodone  toxicity , or other/further treatments as appropriate . 
6.8. Intervention After the End of the Study  
No intervention will be provided to study participants at the end of the study.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 34  
 7. DISCONTINUATION OF STUDY INTERVENTION AND PA RTICIPANT 
DISCONTI NUATION/WITHDRAWAL  
7.1. Discontinuation of Study Intervention  
In rare instances, it may be necessary for a participant  to permanently discontinue 
investigational product .  If investigational product  is permanently discontinued, the 
participant  will not remain in the study .  See the SoA ( Table 2) for data to be collected at the 
time of discontinuation of investigational product . 
SpO 2 Changes  
Participants with an absolute change (drop) in SpO 2 of 4% should be withdrawn fr om the 
study and recorded as an AE.  
EtCO 2 Changes  
Participants with an absolute change (increase) in EtCO 2 of 10  mm Hg should be withdrawn 
from the study and recorded as an AE.  
ECG  Changes  
If the EC G of a participant  meets the bulleted criteria below , then two more ECGs will be 
performed .  If the average of the three ECGs meets the bulleted criteria below, the participant 
is to be withdrawn from the study.  
• QT, QTcF >500 msec. 
• Change from baseline: QTc F >60 msec. 
If a clinically significant finding is iden tified (including, but not limited t o, changes from 
baseline in QT cF after enrollment ), the investigator or qualified designee will determine if 
the participant can continue in the study and if any change in participant management is 
needed.  This review o f the ECG printed at the time of col lection must be documented.  Any 
new clinically relevant finding should be reported as an AE.  
See the SoA ( Table 2) for data to be collected at the time of intervention discontinuation and 
follow -up and for any further evaluations that need to be completed.  
Potential Cases of Acute Kidney Injury  
Abnormal v alues in serum creatinine (SCr) concurrent with presence or absence of increase  
in blood urea nitrogen (BUN) that meet the criteria below, in th e absence of other causes of 
kidney injury, are considered potential cases of acute kidney injury and should be considered 
important medical events.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 35  
 An increase of 0.3 mg/dL (or 26.5 mol/L) in SCr  level relative to the participant’s own 
baseline measur ement should trigger another assessment of SCr as soon as practically 
feasible, preferably within 48  hours from awareness.  
If the second assessment (after the first observations of 0.3 mg/dL [or 26.5 mol/L ] in SCr  
relative to the participant’s own basel ine measurement) is 0.4 mg/dL (or 35.4 mol/L), the 
participant should be discontinued from the study and adequate, immediate, supportive 
measures taken to correct apparent acute kidney injury.  
Parti cipants should return to the investigator site and be e valuated as soon as possible, 
preferably within 48  hours from awareness of the second assessment confirming abnormal 
SCr result.  This evaluation should include laboratory tests, detailed history, and physical 
assessment.  In addition to repeating SCr, lab oratory tests should include serum BUN, serum 
creatine kinase, and serum electrolytes (including at a minimum potassium, sodium, 
phosphate/phosphorus, and calcium), in addition to urinary dipstick, uri ne microscopic 
examination, and urinary indices.  All c ases confirmed on repeat testing as meeting the 
laboratory criteria for acute kidney injury, with no other cause(s) of laboratory abnormalities 
identified, should be considered potential cases of drug -induced kidney injury irrespective of 
availability of a ll the results of the investigations performed to determine etiology of the 
abnormal SCr.  If [ADDRESS_1090772] 2  consecutive  
SCr results of 0.3 mg/dL (or 26.5 mol/L), an assessment of whether the finding may be  
considered an adverse drug reaction should be undertaken.  
Pregnancy  
In the case of a positive confirmed pregnancy, the participant  will be withdrawn from the 
study . 
7.2. Participant Discontinuation/ Withdrawal  from the Study   
A participant may withdraw from the  study at any time at his/her own request  or may be 
withdrawn at any time at the discretion of the investigator for safety, behavioral, compliance, 
or administrative reasons.   At the time of discontinuing from the study, if possible, an early 
discontinuati on visit should be conducted .  See the SoA ( Table 2) for assessments  to be 
collected at the time of study discontinuation and follow -up and for any further evaluations 
that need to be completed.  
The early discontinuation  visit app lies only to participants who are randomized and then are 
prematurely withdrawn from the stud y.  Participants should  be questioned regarding their 
reason for withdrawal.   The participant will be permanently discontinued both from the study 
intervention and  from the study at that time.  
If a participant withdraws from the study, he/she may request d estruction of any remaining 
samples, but data already generated from the sample s will continue to be available  and may 
be used to protect the integrity of existing  analyses.   The investigator must document any 
such requests in the site study records.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 36  
 If the participant withdraws from the study and withdraws consent (see below) for disclosure 
of future information, no further evaluations should be performed,  and no a dditional data 
should be collected.  The sponsor may retain and continue to use any data coll ected before 
such withdrawal of consent.  
When a participant  withdraws from the study because of an SAE, the SAE must be recorded 
on the CRF and reported on the Clinical Trial ( CT) SAE Report.  
Lack of completion of all or any of the withdrawal/early termination procedures will not be 
viewed as protocol deviations so long as the participant ’s safety was preserved.  
Withdrawal of Consent:  
Participant s who request to di scontinue receipt of study tr eatment will remain in the study 
and must continue to be followed for protocol -specified follow -up procedures.  The only 
exception to this is when a participant  specifically withdraws consent for any further contact 
[CONTACT_791280].  Participant s should notify the investigator in writing of the decision to 
withdraw consent from future follow -up, whenever possible.  The withdrawal of consent 
should be  explained in detail in the m edical records by [CONTACT_093], as to whether the 
withdrawal is only from further receipt of investigational product or also from study 
procedures and/or posttreatment study follow -up, and entered on the appropriate CRF pag e.  
In the event that vital s tatus (whether the participant  is alive or dead) is being measured, 
publicly available information should be used to determine vital status only as appropriately 
directed in accordance with local law.  
7.3. Lost to Follow up  
A parti cipant will be considered los t to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298].  
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit:  
• The site must attemp t to contact [CONTACT_791281]/or sh ould 
continue in the study ; 
• Before a parti cipant is deemed lost to follow -up, the investigator or designee must 
make every effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary, a certified letter to the partici pant’s last known mailing 
address or local equivalent methods).  These contact [CONTACT_14316]’s medical record ; 
• Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study.   
PF-[ADDRESS_1090773] dose during  Qualif ication Phase  
to confirm tha t they meet the study population  criteria for the study.  The investigator (or an 
appropriate delegate at the investigator site) must  obtain a signed and dated ICD before 
performing any study -specific procedures.   If the time be tween screening and  dosing exceeds 
28 days as a result of unexpected delays (eg, delayed drug shipment), then participant s do not 
require rescreening if the laboratory results  obtained prior to first dose administration  meet 
eligibility cri teria.  
A partici pant who qualified  for this protocol but did not enroll from an earlier cohort /group  
may be used in a subsequent cohort /group  without rescreening , provided  laboratory results 
obtained prior to the first dose administration meet eligibility criteria  for thi s study .  In 
addition, other clinical assessments or specimen collections, eg, banked biospecimens, may 
be used without repeat collection, as appropriate.  Study procedures and their timing are 
summarized in the Schedule of Activities  (SoA) .  Protocol  waivers or exemptions are not 
allowed.  
Immediate safety concerns should be discussed with the sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue study 
intervention.  
Adherence to the s tudy design requirements, including those specified in the Schedule of 
Activities  (SoA) , is essential and  required for study conduct.  
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all e ligibility criteria.  The investigator will maintain a screening log to 
record details of all participants screened and t o confirm eligibility or record reasons for 
screening failure, as applicable.  
Every effort should be made to ensure that protocol -requi red tests and procedures are 
completed as described.  However, it is anticipated that from time to time there may be 
circumstances outside the control of the investigator that may make it unfeasible to perform 
the test.  In these cases, the investigator mu st take all steps necessary to ensure the safety and 
well-being of the participant .  When a protocol -required test cannot  be performed, the 
investigator will document the reason for the missed test and any corrective and preventive 
actions that he or she h as taken to ensure that required processes are adhered to as soon as 
possible.  The study team must be informed of these incidents in a timely manner.  
Vital signs (HR, BP, RR), SpO 2 and EtCO 2 and AEs will be determined within 10 minutes 
before the nominal time points.  
PD measures (ie, VAS) will be administered at the nominal time points (±5 minutes), 
followed by [CONTACT_584567][INVESTIGATOR_115726] . 
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 38  
 PK sample collection will occur within approximately 5 minutes of completion of 
pupi[INVESTIGATOR_791250]  (see 
Section  8.5). 
All pre -dose measures will be obtained within 30 minutes before dosing.  
If an intravenous (IV) catheter is utilized for blood sample collections, baseline ECGs and /or 
vital sign assessments  (pulse rate and BP) should be collected prior to the insertion of the 
catheter . 
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact [CONTACT_791282].  
The total blood sampling volume for individual participant s in this study is approximately 
508 mL for male participant s and 528 mL for female participant s.  The actual collection 
times of blood sampling m ay change.  Additional blood samples may be taken for safety 
assessments at times specified by [CONTACT_2728] , provided the total volume taken during the study 
does not exceed 550  mL during any period of 60  consecutive days . 
To prepare for s tudy participation, participant s will be instructed on the information in the 
Lifestyle Considerations  and Concomitant Therapy  sections  of the protocol.  
8.1. Efficacy Assessments  (Not applicable)  
8.2. Safety Assessme nts 
Planned time points for all safety assessments are provided in the Schedule of Activities  
(SoA) .  Unscheduled clinical laboratory measurements may be obtained at any time during 
the study to assess any perceived safety concerns.  
8.2.1.  Physica l Examinations  
A complete  physical examination will include , at a minimum,  head, ears, eyes, nose, mouth, 
skin, heart and lung examinations, lymph nodes, and gastrointestinal, musculoskeletal, and 
neurological systems.  
A brief  physical examination will include, at a minimum, assessments of  general appearance, 
the respi[INVESTIGATOR_110251], and participant -reported symptoms.   
Physical  examinations may be conducted by a physician, trained physician's assistant, or 
nurse practitioner as acceptabl e according to local regulation.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 39  
 Height and weight will also  be measured and recorded  as per the Schedule of Activities  
(SoA) .  For measuring weight, a scale with appropriate range and resolution is used and must 
be placed on a stable, fla t surfac e.  Participant s must remove shoes, bulky layers of clothing, 
and jackets s o that only light clothing remains.  They must also remove the contents of their 
pockets and remain still during measurement of weight.  
8.2.2.  Vital Signs  
Sitting BP will be measu red with the participant ’s arm supported at the level of the heart , and 
recorded to the nearest mm  Hg after approximately [ADDRESS_1090774] .  The same arm 
(preferably the dominant arm) will be used throughout the study.  Participant s should b e 
instructed n ot to speak during measurements.  
The same properly sized and calibrated BP cuff will be used to measure BP each time.  The 
use of an automated device for measuring BP  is acceptable.  Pulse rate and oxygen saturation 
will be measured sitting with a pulse ox imeter.   When the timing of these measurements 
coincides with a blood collection, BP , pulse oximetry and respi[INVESTIGATOR_791251].   
Pulse  and respi[INVESTIGATOR_109651], oxygen saturation, d iastolic and s ystolic blood pressure will be 
monitored post -drug (see SoA).  These measures are done in abuse liability testing to ensure 
safety.  
Additional collection times, or changes to collection times , of BP, pulse oximetry and 
respi[INVESTIGATOR_591796], as necessary, to ensure appropriate collection of safety 
data.  
The procedure for collecting postural or orthostatic data will be:  
• Assess BP after the participant  is in the supi[INVESTIGATOR_19636] a minimum of 5  minutes ; 
• Have the particip ant stand up for 2  minutes ; 
• Assess BP after the participant  is in the standing position  for approximately 
2 minutes.  
Orthostatic hypotension is defined as a decrease of 20 mm Hg for systolic BP or 
[ADDRESS_1090775] posture from a supi[INVESTIGATOR_591798]: lightheadedness, di zziness, blurred vision, w eakness, fatigue, cognitive impairment, 
nausea, palpi[INVESTIGATOR_814], tremulousness, headache, and/or neck ache.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 40  
 If a participant  has symptoms suggestive of orthostasis , but not documented orthostatic 
hypotension, repeated measurements of supi[INVESTIGATOR_050]/standing BP should  be obtained.  Lesser 
degrees of BP reduction may still be considered clinically significant if the participant  
becomes symptomatic upon standing, especially in  the presence of a significant increase in 
pulse rate  (30 beats per minute  [bpm]).  
[IP_ADDRESS].  Respi[INVESTIGATOR_791252] (RR, breaths/min), pulse oximetry, tidal volume (VT , mL) and end -tidal 
carbon dioxide (EtCO 2, mmHg) will be measured continuously, pre -dose to [ADDRESS_1090776] -dose during the Treatmen t Phase (see SoA). 
[IP_ADDRESS].  Temperature   
Temp erature will be measured orally  or with a tempo ral infrared scanner .  No eating, 
drinking, or smoking is allowed for [ADDRESS_1090777] dose as specified in the Schedule of Activities  (SoA) .  
Pupi[INVESTIGATOR_791253] 0.25, 1,  1.52, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 
[ADDRESS_1090778] -drug.  These measures are done in abuse liability testing to verify 
dosing.  
8.2.4.  Electrocardiograms  
Twelve ( 12)-Lead E CGs should be colle cted at times specified in the Schedule of Activities  
(SoA)  using an ECG machine that automatically calculates the heart rate and measures PR, 
QT, and QTc intervals  and QRS complex .  All scheduled ECGs should be performed after 
the particip ant has rested quietly for at least 10  minutes in a supi[INVESTIGATOR_2547].  
To ensure safety of the participant s, a qualified individual at the investigator site will make 
comparisons to baseline measurements.  Additional ECG monitoring will occur if a) a 
post-dose QTc F interval is increased by 30 msec from the baseline and is >450  msec; or 
b) an absolute QT value is [ADDRESS_1090779]-dose QTc F interval remains  ≥30 msec from the baseline and is >450  msec; or b) an 
absolute QT value is ≥500 msec for any scheduled ECG  for greater than 4  hours (or sooner, 
at the discretion of the investigator), or QTc F intervals get progressively longer, the 
participant  should undergo continuous ECG monitoring.  A cardiologist should be consulted 
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 41  
 if QTc intervals d o not return to less than  the criterion listed above after 8  hours of 
monitoring (or sooner, at the discretion of  the investigator).   
In some cases, it may be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the EC G abnormality.  It is important that leads be placed in the 
same positions each time in order to achieve precise ECG recordings.  If a machine -read QTc 
value is prolonged, as defined above, repeat measurements may not be necessary if a 
qualified medical pr ovider’s interpretation determines that the QTc F values are in the 
acceptable range.  
ECG values  of potential clin ical concern are listed in  Appendix 7. 
[IP_ADDRESS].  Continuous Cardiac Monitoring by [CONTACT_791283] (Table 2).  The t ime, duration, and description of any clinically s ignificant abnormal 
rhythm  will be reported as an adverse event  using Appendix [ADDRESS_1090780] of clinical safety laboratory tests to be performed and the 
Schedule of Activities  (SoA)  for the timing and f requency.  
The investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the CR F.  
Clinically significant abnormal laboratory findings are those which are  not associated with 
the underlying disease, unless judged by [CONTACT_78259]'s condition.  
All laboratory tests with values cons idered clinically significantly abnormal during 
participation in the study or within [ADDRESS_1090781] dose of study intervention 
should be repeated until the values return to normal or baseline or are no longer considered 
clinically significant  by [CONTACT_10982].  
If such values do not return to no rmal/baseline within a period of time judged reasonable by 
[CONTACT_093], the etiology should be identified and the sponsor notified.  
All protocol -required laboratory assessments, as defined in Appendix [ADDRESS_1090782]  be conducted 
in accordance with the laboratory manual and the Schedule of Activities  (SoA) .  
If laboratory values from non -protocol -specified laboratory assessments performed at the 
institution’s local laboratory require a change in partic ipant management or are considered 
clinically signifi cant by [CONTACT_093] (eg, SAE or AE or dose modification), then the 
results must be recorded in the CRF.  
PF-[ADDRESS_1090783] .  
8.2.6.  Suicidal Ideation and Behavior Risk Monitoring   
[IP_ADDRESS].  Columbia Suicidality Severity Rating Scale (C -SSRS)  
The Columbia Suicide -Severity Rating Scale (C -SSRS) will be collected at timepoints on the 
Schedule of Activities  (SoA) .  The C -SSRS is being used in the current study to provide a  
summary measure of suicidal ideation and behavior risks.  This scale is to be completed by 
[CONTACT_32341].  Training materials on the scale will be provided to investigator sites by 
[CONTACT_2728] . 
[IP_ADDRESS].  Risk Assessment During Screening  
The Investigator will review the results of the C -SSRS (baseline), and medical history.  The 
following criteria would indicate a potential su icide risk:  
• Suicidal ideation associated with actual intent and/or method and/or plan and/or 
action (eg, self -harming behaviors) in the past year based on C -SSRS assessment  
(“yes” answers on items 4 or 5 of the C -SSRS).  
• Any previous history of  suicide beh aviors reported or documented within the past  
10 years.  
• For events that occurred within the past 5 years, an answer of “yes” to any of the 
suicidal behavior items of the C -SSRS).  
• Investigator’s judgment.  
If any of these criteria are met and the participant  is being considered for study participation, 
a risk assessment must be completed to determine whether it is appropriate for the participant  
to be enrolled.  
Risk assessments should be done by a qualified mental health professional (MHP)  with 
appropriate  training in the assessmen t of suicide risk (according to the local clinical practice 
standards  and regulations) and who would normally evaluate the risk for suicide for a 
participant . 
The MHP may be a member of the study site team.  If an MHP is not availabl e within the  
study team , the Investigator should make the necessary referral.  
The Investigator must obtain and review the risk assessment prior to the participant  being  
randomized.  A written copy of the risk assessment should be included in the participan t’s 
clinical record (source documentation).  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 43  
 [IP_ADDRESS].  Risk Assessment During the Study  
Beginning with Period  1, if there are any “yes” responses on items  4, 5 or on any behavioral  
question of the C -SSRS (since last visit), a risk assessment should be done by a quali fied 
MHP to determine whether it is safe for the participant  to continue to participate in the trial.   
Suicidal risk should be managed appropriately by [CONTACT_591829]  a qualified  
MHP (or the Investigator alone if the Investigator is a quali fied MHP).  In addition, the  
Investigator should consult with the Sponsor  medical monitor to determine whether the 
participant  can continue in the trial.  
A narrative should be prepar ed for participant s who have undergone any post -baseline risk  
assessment, using information from the C -SSRS.  
8.2.7.  Pregnancy Testing  
Pregnancy tests may be urine or serum tests, but must have a sensitivity of at least 
25 mIU/mL.  Pregnancy tests will be performed in women of childbearing potential 
(WOCBP ) at the times listed in the Schedule of Activities  (SoA) .  Following a negative  
pregnanc y test result at screening, appropriate contraception must be commenced and a 
second negative pregnancy test result will be required at the baseline visit prior the 
participant ’s receiving the study treatment.  Pregnancy tests will also be done whenever 
1 menstrual cycle is missed during the active treatment period (or when potential pregnancy 
is otherwise suspected) and at the end of the study.  Pregnancy tests may a lso be repeated if 
requested by [CONTACT_110453] (IRBs)/ethics committees (ECs) or if required by 
[CONTACT_427].  If a urine test cannot be confirmed as negative (eg, an ambiguous result), a 
serum pregnancy test is required.  In such cases, the participant must be excluded if the 
serum pregnancy result is positive.  
8.3. Adverse Events and Serious Adverse Events  
The definitions of an AE and an  SAE can be found in Appendix 3 . 
AEs will be reported by [CONTACT_238519] (or, when appropriate, by a caregiver, surrogate, or 
the participant's legally authorized representative).  
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events th at meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether it 
meets the criteria for classification as an SAE or that caused the participant to discontinue the  
study  (see Section 7).  
In addition, the investigator may be requested by [CONTACT_22835] -up 
information in a n expedited fashion.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 44  
 8.3.1.  Time Period and Frequency for Collecting AE and SAE Information  
The ti me period for actively eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant  begins from the time the participant  provides informed  consent, 
which is obtained before the participant ’s participation in the study (ie, before  undergoing 
any study -related procedure and/or receiving investigational product), through and including 
a minimum of [ADDRESS_1090784].  
For participant s who are screen  failures, the active collection period ends when screen failure 
status is determined.  
Medical occurrences that begin before the start of study intervention but a fter obtaining 
informed consent will be recorded on the Medical History/Current Medical Condit ions 
section of the CRF, not the AE section.  
Follow -up by [CONTACT_74095] a level acceptable to the investigator, and 
[COMPANY_007] concurs wi th that assessment.  
Investigators are not obligated to actively seek AE or SAE after conclusion of the study 
participation .  However, if the investigator learns o f any SAE, including a death, at any time 
after a participant has been discharged from the stu dy, and he/she considers the event to be 
reasonably related to the study intervention or study participation, the investigator must 
promptly notify the sponsor.  
[IP_ADDRESS].  Reporting SAEs to [COMPANY_007] Safety  
All SAEs occurring in a participant  during the active collectio n period are reported to [COMPANY_007] 
Safety on the CT SAE Report Form i mmediately and under no circumstance should this 
exceed 24 hours, as indicated in Appendix 3 .  The investigator will submit any updated SAE 
data to the sponsor within 24  hours of it being available.  
SAEs occurring in a participant after the active collection period has ended are reported to 
[COMPANY_007] Safety if t he investigator becomes aware of them; at a minimum, all SAEs that the 
investigator believes h ave at least a reasonable possibility of being related to investigational 
product must be reported to [COMPANY_007] Safety.  
[IP_ADDRESS].  Recording Non -serious AEs and SAEs on the CRF  
During the active collection period, both non -serious AEs and SAEs are recorded on the 
CRF.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 45  
 8.3.2.  Method of Detecting AEs and SAEs  
The method of recording, evaluating, and assessing causality of AE s and SAE s and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 . 
Care will be t aken not to introduce bias when detecting AEs and/or SAEs.   Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences.  
8.3.3.  Follow -up of AEs and SAEs  
After the initial AE/SAE report, the investigator  is required to proactively follow each 
participant at subsequent visits/contacts.  For each event, the inve stigator must pursue and  
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost t o follow -up (as defined in Section 7.3). 
In general, follow -up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and i ndependent determination of 
possible causality.  Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided.  In the case of a participant  death, a summary of available 
autopsy findings must be submitted as soon as possible to [COMPANY_007] Safety .  
Further information on follow -up procedures is given in Appendix 3 . 
8.3.4.  Regulatory Reporting Requirements for SAEs  
Prompt notification by [CONTACT_11012] a n SAE is esse ntial so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a 
study intervention under clinical investigation are met.    
The sponsor has a legal responsibility to notify both the local regulatory author ity and other 
regulatory agencies about the safety of a study intervention under clinical investigation.  The 
sponsor will comply with country -specific regulatory requirements  relating to safety 
reporting to the regulatory authority, institutional review boards (IRB s)/ethics committees 
(ECs), and investigators.  
Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]R s) according to local regulatory requirements and sponsor policy and 
forwarded to investigators a s necessary.  
An investigator who receives an investigator safety report describing a n SAE or other 
specific safety information (eg, summary or listing of SAEs) from the sponso r will review 
and then file it along with the SRSD for the study investigator’s brochure and will notify the 
IRB/EC, if appropriate according to local requirements.  
PF-[ADDRESS_1090785] under study during pregnancy or breastfeeding and 
occupational  exposure are reportable to [COMPANY_007] Safety within 24 hours of investigator 
awareness.  
[IP_ADDRESS].  Exposure During Pregnancy  
Details of all pregnancies in female participants and, if indica ted, female partners of male 
participants will be collected after the start of st udy intervention and until [ADDRESS_1090786] . 
If a pregnancy is reported, the investigator should inform the sponsor within 24 hours of 
learning of the pregnancy and should follow the procedures outlined in Appendix 4 . 
Abnormal pregnancy outcomes (eg, spon taneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered SAEs.  
[IP_ADDRESS].  Exposure During Breastfeeding  
Scenarios of e xposure during breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to [COMPANY_007]  Safety within 24 hours of the investigator’s awareness, using the 
CT SAE Report Form.  An exposure during breastfeeding report is not created when a  [COMPANY_007] 
drug specifically approved for use in breastfeeding women (eg, vitamins) is administered in 
accord with authorized use.  However, if the infant experiences an SAE associated with such 
a drug’s administration, the SAE is reported together with the e xposure during breastfeeding.  
[IP_ADDRESS].  Occupational Exposure  
An occupational exposure occurs when, during the perfor mance of job duties, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact [CONTACT_8898], which may or may no t lead to the occurrence of an AE.  
An occupational exposure is reported to [COMPANY_007] Safety within 24 hours of  the investigator’s 
awareness, using the CT SAE Report Form, regardless of whether there is an associated 
SAE.  Since the information does not pertai n to a participant  enrolled in the study, the 
information is not recorded on a CRF; however, a copy of the completed CT SAE Report 
Form is maintained in the investigator site file . 
8.3.6.  Medication Errors  
Medication errors may result from the administration or c onsumption of the investigational 
product by [CONTACT_19995] , or at the wrong time, or at the wrong d osage strength .   
Exposures to the investigational product under study may occur in clinical trial settings, such 
as medication errors.  
PF-[ADDRESS_1090787] SAE Report 
Form to [COMPANY_007] Safety Within 
24 Hours of Awareness  
Medication errors  All (regardless of whether 
associated with an AE)  Only if associated with an SAE  
Medication errors include:  
• Medication errors involvin g participant  exposure to the investigational product;  
• Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study  participant . 
Such medication errors occurring to a study participant are to be captur ed on the med ication 
error page of the CRF, which is a specific version of the AE page.  
In the event of a medication dosing error, the sponsor should be notified immediately.  
Whether or not the medication error is accompanied by [CONTACT_1149], as determined by [CONTACT_2924] , the medication error is recorded on the medication error page of the CRF and, if 
applicable, any associated AE(s), serious and non -serious, are recorded on an AE page of the 
CRF.    
Medication errors should be reported to [COMPANY_007] Safety within  [ADDRESS_1090788] SAE Report 
Form only when associated with an SAE.  
8.4. Treatment of Overdose  
For this study, any dose of Neurontin® >1200 mg  or oxycodone HCl >20 mg  within a 
24-hour time period will be considered an overdose.  
Sponsor does not recommend specif ic treatment for an overdose . 
In the event of an overdose, the investigator  should:  
1. Contact [CONTACT_10990].  
2. Closely monitor the participant for any AE s/SAE s and laboratory abnormalities until 
gabapentin  and oxycodone can no longer be detec ted systemically (at least 3 days).  
3. Obtain a blood  sample for PK analysis within [ADDRESS_1090789] dose of 
study intervention if requested by [CONTACT_7195] (determined on a case -by-case 
basis).  
4. Document the quantity of the excess dose as well as the duration of the overdose in 
the CRF.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 48  
 5. Overdose is reportable to Safety only when associated with a n SAE.  
Decisions regarding dose interruptions or modifications will be made by [CONTACT_791284] o n the clinical evaluation of the participant.  
8.5. Pharmacokinetics  
Blood  samples of approximately 5 mL, to provide a total of approximately 2  mL of plasma 
volume,  will be collected for measurement of plasma  concentrations of gabapentin  and 
oxycodone as specif ied in the Schedule of Activities  (SoA) .  Instructions for the collection 
and handling of biological samples will be provided in the lab oratory  manual or by [CONTACT_103].  The actual date and time (24 -hour clock time) of each sample will be recorded.  
The actual times may change, but the number of samples will remain the same.  All efforts 
will be made to obtain the samples at the exact nominal time relative to dosing.  Collection of 
samples up to and including 10  hours after dose administrati on that are  obtained within 
10% of the nominal time (eg, within 6  minutes of a 60 -minute sample) relative to  dosing will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and data collectio n tool (eg,  CRF).   Collection of samples  more than 
10 hours after dose administration  that are  obtained ≤[ADDRESS_1090790] time of the 
collection is noted  on the source document and data collection tool (eg,  CRF ).  
Samples will be used to evaluate the PK of gaba pentin  and oxycodone .  Samples collected 
for analyses of gabapentin  and oxycodone plasma concentration may also be used to evaluate 
safety or effica cy aspects related to concerns arising during or after the study, for metabolite 
identification and/or evalu ation of the bioanalytical method, or for other internal exploratory 
purposes.  
Genetic analyses will not be performed on these plasma  samples.  Part icipant confidentiality 
will be maintained.  
Samples collected for measurement of plasma  concentrations of gabapentin  and oxycodone 
will be analyzed using a validated analytical method in compliance with applicable standard 
operating procedures (SOPs).  
The PK samples must be processed and shipped as indicated  in the instructions provided to 
the investigator site to maintain sample integrity.   Any deviations from the PK sample 
handling procedure (eg, sample collection and processing steps, interim storage or shippi[INVESTIGATOR_15889]), including any actions taken, mu st be documented and reported to the sponsor.  
On a case -by-case basis, the sponsor may make a determination as to whether sample 
integrity has been compromised.  
Drug concentration information that may u nblind the study will not be reported to 
investigator  sites or blinded personnel until the study has been unblinded.  
PF-[ADDRESS_1090791] 
be documented and approved by [CONTACT_249220] y team member and then archived in the 
sponsor and si te study files, but will not constitute a protocol amendment.  The IRB/EC will 
be informed of any safety issues that require alteration of the safety monitoring scheme or 
amendment of the ICD.  
8.6. Pharmacody namics  
8.6.1.  Subjective  Effects  
The questionnaire described  below is used in drug abuse as well as clinical efficacy and 
toxicity evaluation of pharmacologic agents, and its usefulness is widely accepted.  
Furthermore, previous results indicate that the instrume nt is sensitive, reliable, and valid.  
[IP_ADDRESS].  Visual  Analog  Scale  (VAS)   
The VAS consists of horizontal 100 -mm lines, each labeled with an adjective such as “Drug 
Liking” or “Hi gh”, etc .  Participants will be instructed to place a mark on each line indicating 
how they feel at the moment.  For example, for “Drug Liking” the participant will be 
asked: At this moment, my liking for this drug is ?  The participant will then rate on the 0 to 
100 scale, where: Strong disliking = 0; Neither like nor Dislike = 50; and  
Stron g Liking = 100.  
Primary En dpoints : 
• VAS for Drug Liking presented on a bipolar 0 to 100 scale.  
Secondary Endpoints : 
• VAS for High presented on a unipolar 0 to 100 scale.  
• VAS for Take Drug Again presented on a bipolar 0 to 100 scale.  
• VAS for Overall Drug Liki ng presented on a bipolar 0 to 100 scale.  
• VAS for Any Drug Effects, Good Effects, and Bad Effects presented on unipolar 0 to 
100 scales.  
8.7. Genetics  
8.7.1.  Specified Genetics  
Genetics (s pecified analyses)  are not evaluated in this study.  
8.7.2.  Banked Biospecimens for Gene tics 
A 4-mL blood sample o ptimized for deoxyribonucleic acid (DNA) isolation Prep D1 will be 
collected as local regulations and IRBs/ECs allow.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 50  
 Banked biospecimens may be used for research related to drug response.  Genes and other 
analytes (eg, proteins,  ribonucleic acid (RNA), n ondrug metabolites) may be studied using 
the banked samples.  
Unless prohibited by [CONTACT_168086]/EC decision, participants will be asked to 
indicate on the consent document whether they will allow their banked biospecim ens to also 
be used to des ign and conduct research in order to gain a further understanding of other 
diseases and to advance science, including development of other medicines for patients.  This 
component of the sampling banking is optional for participant s; they may still particip ate in 
the study even if they do not agree to the additional research on their banked biospecimens.  
The optional additional research does not require the collection of any further samples.  See 
Appendix 5  for infor mation regarding genetic research.  Details on processes for collection 
and shipment of these samples can be found in the Lab Manual.  
8.8. Biomarkers  
Biomarkers are not evaluated in this study.  
8.9. Health Economics  
Health economics/ medical  resource utilization and health economics  parameters are not 
evaluated in this study.  
9. STATISTIC AL CONSIDERATION S 
Detailed methodology for summary and statistical analyses of the data collected in this study 
is outlined here and further detailed in a statistical analysis plan (SAP), which will be 
maintained by [CONTACT_456].  The SAP may modify what is outlined in the protocol where 
appropriate; however, any major modifications of the primary endpoint definitions or their 
analyses will also be ref lected in a protocol amendment.  
The Statistical Analysis Plan  will be developed and finalized before database lock and will 
describe the participant populations to be included in the analyses, and procedures for 
accounting for missing, unused, and spurious data.   
9.1. Statistical Hypothesis  
To assess the abuse potential of gabapentin the following tests will be performed  in the order 
of validation test followed by [CONTACT_791285]. oxycodone and then gabapentin alone vs. 
oxycodone : 
Study Validation:   
1. The sensitivity and int egrity of the study will be validated by [CONTACT_791286], the positive control (C), to the placebo  (P):  
H0: µ C - µP ≤ δ1 versus H a: µC - µP > δ1 where δ 1 =15. 
Primary:  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 51  
 2. Does gabapentin  plus oxycodone HCl (T) produce mean responses that show abuse 
potential that is no higher than oxycodone  HCl (C)? 
H0: µT - µC ≥ 0.2(µ C - µP) versus H a: µT - µC <0.2(µ C - µP). 
Secondary:  
3. Does gabapentin (G) produce mean responses that show less abuse potential than 
oxycodone  HCl (C)? 
H0: µC - µG ≤ 0.2(µ C - 50) versus H a: µC - µG >0.2(µ C - 50).17 
4. Does gabapentin (G) produce mean responses that show abuse potential similar to 
placebo (P)? 
H0: µG - µP ≥ δ2 versus H a: µG - µP < δ2 where δ 2 =11. 
5. Does gabapentin (G) produce mean responses that show less abuse potential than 
gabapentin plus oxycodone HC l (T)? 
H0: µT - µG ≤ 0.2(µ T - 50) versus H a: µT - µG >0.2(µ T - 50).[ADDRESS_1090792] will be assessed 
for all doses of gabapentin . 
9.2. Sample Size Determination   
Forty two  (42) participants will provide 90%  power to demonstrate the difference between 
gabapentin plus oxycodone HCl and oxycodone HCl alone is no larger than 20% of the 
difference between oxycodone HCl and placebo.  This assumes means  [standard deviation  
(SD) ] of 75.0 (16), 75.0 (16), and 51.6 (6 .77) for gabapentin plus oxycodone HCl, oxycodone 
HCl, and placebo, respectively.  The correlation between gabapentin plus oxycodone HCl is 
assumed to be 0.85.  
A 15 -point VAS E max “Drug Liking” difference between placebo and the positive control 
must be de monstrated for validation of the study.  Thirty six (36) participants  will provide at 
least 90% power to show the positive control (20 mg dose of oxycodone HCl given alone) is 
[ADDRESS_1090793] 90% power for both analyses and to account for participants who 
will be excluded from the Modified Completer Population, [ADDRESS_1090794] 20% will be females to ensure that 
the fi ndings are valid across different populatio ns. 
9.3. Populations for Analysis  
The following populations are planned for this study:  
• The Safety Population will include all participants  who receive at least one dose of 
study  drug, beginning with the Naloxone Challenge.  This population will be 
analyzed as treated.  
• The PK population will include all enrolled participants  treated who have at least  
[ADDRESS_1090795].  
• The Completer Population will include all randomized participants  who complete all  
[ADDRESS_1090796] -dose responses for each treatme nt 
group present until median T max sampling  time after dosing.   
• The Modified Completer Population will include all randomized participants in the 
Completer Population, howev er will exclude any participant who meet either or both  
of the following criteria for Drug Liking VAS:  
1. Emax scores are within 5 a point difference across all six treatments (ie , Maximum 
Emax score – Minimum E max score ≤5) ; 
2. Emax(P) > 60 AND  Emax(P) - Emax(Oxy20) ≥5 ; 
where Emax(P) and Emax(Oxy20) are the VAS Emax scores for placebo and 
oxycodone HCl IR 20 mg, respectively.  
 This population will be analyzed as randomized.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 53  
 • The Evaluable Population will include all ra ndomized participants  in the Completer  
Population who do not have major protocol violations or adverse events that would  
interfere with drug absorption such as vomiting within [ADDRESS_1090797] the PD conclusions of the  
study.  Prior to unblinding the Treatment Phase data, the Sponsor (or designee) will  
identify proto col violations or adverse events that would disqualify a participant  from 
the evaluable population and determine which participants  or participant  visits will be 
excluded.   This population will be analyzed as randomized.  
All PD analyses will be performed u sing the Modified Completer Population and a ll 
available postdose  data; these will be the primary PD analyses.  Key PD analyses may be 
repeated on the  Evaluable Population using all available post -dose data . 
9.4. Statistical Analyses  
Statistically, the study wi ll be evaluated as a safety study.  Conseque ntly, the null hypothesis 
for gabapentin alone and when used concomitantly with oxycodone HC l will be constructed 
on the presumption that these treatments produce abuse potential similar to oxycodone HC l 
and ther efore differentiates from placebo.  To demon strate that these treatments have no 
abuse potential the null hypothesis will be statistically rejected.  
The SAP will be developed and finalized before database lock and will describe the 
participant populations to be included in the analyses, and procedur es for accounting for 
missing, unused, and spurious data.  This section is a summary of the planned statistical 
analyses of the primary and secondary endpoints.  
9.4.1.  Endpoint Analysis  
The following parameters will be calculated for VAS for “Dru g Liking” and VAS  for 
“High”.  D uring the Treatment Period:  
• Maximum (peak) effect ( Emax) for High only ; calculated as maximum change from 
pre-dose response if pre -dose assessment is performed :  
• Time of maximum (peak) effect (T Emax); 
• Area under the effect curve to 1 hour (A UEC 1); 
• Area under the effect curve to 2 hours (AUEC 2); 
• Area under the effect curve to 3 hours (AUEC 3); 
• Area under the effect curve to 4 hours (AUEC 4); 
• Area under the effect curv e to 8 hours (AUEC 8); 
• AUEC last. 
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 54  
 The VAS for “Overall Drug Liking” ,  “Take Drug Again” , “Good Drug Effect”, “Bad Drug 
Effect”, and “ Any Drug Effect”  will be summarized by [CONTACT_591835].  
9.4.2.  Study Validity of Analysis of Endpoints  
Study validity will first be confirmed through the comparison of mean Emax for “Drug 
Liking ” between oxycodone and placebo administered during the Treatment  Phase.  This 
comparison will be made using a mixed -effect model with treatment, period, treatment 
* period interaction, a carryover variable and sequen ce as fixed effects, and participant  
nested within sequence a s a random effect.  If the p -value for the carryover variable is 
>0.25,  a reduced mixed model will be used with treatment, period and sequence as fixed 
effects, and participant nested within sequence as a random effect.  If the treatment 
comparison of oxyc odone vs. placebo is statistically significant (ie,  one-sided  p0.05) in the 
appropriate direction  and confidence intervals exclude differences  of <15 points for “Drug 
Liking ” Emax, it will confirm the sensitivity  of the study.   If study validity is not co nfirmed, 
comparisons between  gabapentin  and oxycodone will not be performed . 
9.4.3.  Analysis of Primary and Secondary Endpoint  
A linear mixed -effect model with treatment, period, treatment * period interaction, a 
carryover variable and sequen ce as fixed effects, and participant  nested within sequence as a 
random effect.  If the p -value for the carryover variable is >0.25, a  reduce d mixed model will 
be used with treatment, period and sequence as fixed effects, and participant nested within 
sequence as a random effe ct.  The primary analyses of abuse potential will be based on 
testing the differences between the means from the primary  measure(s) at the peak of drug 
response effects (VAS E max) produced by [CONTACT_313157] , oxycodone HC l and placebo at a 
significance level of  0.05 (1-sided).  
The primary PD endpoint is the E max of bipolar VAS for “Drug Liking”.  
The principal parameters for the  primary and secondary endpoints will be summarized by 
[CONTACT_791287] (mean, SE, median, first and third quartil es, minimum 
and maximum).   These  parameters will be analyzed using a mixed -effect model with 
treatment, period, treatmen t * period interaction, a carryover variable and sequen ce as fixed 
effects, and participant  nested within sequence as a random effect.  If the p -value for the 
carryover variable is >0.25, a  reduced  mixed model will be used with treatment, period and 
sequen ce as fixed effects, and participant nested within sequence as a random effect.   
Analyses of endpoints with baseline (pre -dose) measurem ents will include the baseline  
measurement as a covariate in the model.  Least squares means, standard errors, and 
one-sided 95% confidence intervals will be provided for each treatment and for the 
difference between  treatments.  P-values will be provided for each hypothesis.  A two-sided 
95% confidence interval will be provided for the comparisons of gabapentin (600 mg an d 
1200 mg) plus oxycodone versus oxycodone IR 20 mg.  Data will be summarized 
graphically, where appropriate.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 55  
 The study validation  compar isons will be:  
• oxycodone 20 mg vs. placebo.   
The primary treatment comparisons will be:  
• gabapentin 600 mg plus oxycodo ne IR 20 mg vs. oxycodone IR 20 mg; 
• gabapentin 1200 mg plus oxycodone IR 20 mg vs. oxycodone IR 20 mg. 
The secondary treatment comparison s will be:  
• gabapentin 600  mg vs. placebo;  
• gabapentin 1200  mg vs. placebo;  
• gabapentin 600 mg plus oxycodone IR 20 mg vs. placebo;  
• gabapentin 1200 mg plus oxycodone IR 20 mg vs. placebo;  
• gabapentin 600  mg vs. oxycodone IR 20 mg; 
• gabapentin 1200  mg vs. oxycod one IR 20 mg; 
• gabapentin 600 mg plus oxycodone IR 20 mg vs. gabapentin 600  mg; 
• gabapentin [ADDRESS_1090798] ed using one tailed significance criteria.  These compa risons will be used to assess 
the primary study objective.  
Regression diagnostics will be performed to verify model assumptions and adequacy of the 
fitted linear models for the primary endpoints.  Leve ne’s test will be used to diagnose 
potential heterogene ity of variance and the Shapi[INVESTIGATOR_2152] –Wilk test will be used to diagnose 
potential non -normality of the model residuals.  
If the resulting p -value from Levene’s test is ≤0.05, the null hypothesis of equal var iances is 
rejected and it will be concluded that there is a difference between the treatment group 
variances.  An unequal variance model will then be applied using the Sa tterthwaite method in 
order to produce an accurate F -approximation.  
If the resulting p -value from the Shapi[INVESTIGATOR_2152] -Wilk test is ≤0.05, symmetry of  the distribution of 
paired differences will be tested using the Triples Test  and either the t test (symmetry) or s ign 
test (asymmetry) will be performed.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 56  
 [IP_ADDRESS].  Pharmacodynamic Analysis  
Pharmacodynamic parameter values that will be evaluated are listed in  Table  4.  The 
pre-dose measurements of psychometric and pupi[INVESTIGATOR_791254].  Descriptive statistics for the 
changes from baseline will be reported by [CONTACT_591836].  The changes 
from baseline will be analyzed with an analysis of variance ( ANOVA ) model consisting of: 
Sequence, Period, Treatment, Time, Period*Time a nd Treatment*Time terms as fixed 
effects, and a participant (Sequence) term as a random effect.  To accommodate the repeated 
measures aspect of the design, a compound symmetric covariance  matrix will be employed, 
with the participant set to Period*Particip ant (Sequence).  The Treatment*Time least -squares 
means and differences among them will be assessed for trends likely to be of clinical 
relevance.  
Descriptive statistics of the mean, stan dard error, and other summary statistics such as 
minimum, first quart ile (Q1), median, third quartile (Q3) and maximum for each subjective  
measure, each treatment and each paired difference among treatments will be calculated and 
used to create tables and graphs.  
Pupil size will be summarized by [CONTACT_150746].  
As an explorat ory analysis , the time course of the different subjective measures in relation to 
each other (and to abuse -related AEs) will evaluate the outcome of positive or negative 
assessments of th e drug before, during and after the peak of drug effects.  The physio logical 
effects such as pulse  rate, blood pressure, respi[INVESTIGATOR_791255] d and the 
PK of the drug.  
[IP_ADDRESS].1.  Derivation of Pharmacodynamic Parameters   
PD parameters for VAS “Drug Liking” and “High” will be derived from the effect -time 
profiles as shown in  Table  4. 
Table  4. Derivation of Pharmacodynamic Parameters  
Parameter  Definition  Method of Determination  
Emax Maximum effect  Observed  directly from data  
TE max Time for Emax Observed  directly from data as time 
of first occurrence  
AUEClast Area under the effect -time profile from time 
zero to the time of the last quantifiable 
effect  (Elast) Linear trapezoidal method  
AUE C1 Area under the effect -time profile from time 
zero to [ADDRESS_1090799] -time profile from time 
zero to 8 hour s postdose  Linear trapezoidal method  
 
[IP_ADDRESS].  Pharmaco kinetic A nalysis  
Blood samples will be collected throughout the study session in order to monitor drug PK.  
This will be done to primarily confirm that plasma levels  of the drug are equivalent between 
participant s and to evaluate whether subjective measures and AEs can be correlated with 
drug levels over time.  Typi[INVESTIGATOR_408699], blood will be drawn immediately after the collection of 
subjective measures are completed at each  time point.  If an analysis shows that a participant 
had low plasma levels of a drug, it may account for a lack of subjective responses in a drug 
session .  
[IP_ADDRESS].1.  Pharmacokinetic Parameters  
Gabapentin  and oxycodone PK parameter values will be calculated for each  non-placebo 
treatment and each participant using noncompartmental analysis of  concentration -time data. 
PK parameter values that will be evaluated are lis ted in Table  5.  The PK parameters 
(AUC inf, AUC last, Cmax, Tmax, t½, partial AUCs [AUC 1, AUC 2, AUC 3, AUC 4, AUC 8]) will be 
derived for each participant /period/analyte and will be summarized by [CONTACT_791288].  
Individual participant  PK parameters, as well as summary statistics (eg, group averages, SD, 
geometric means, coeffic ient of variation [CV]  and geometric CV% ) by [CONTACT_791289] f or PK  parameters, as appropriate.  Plasma concentration -time profiles of 
gabapentin  and oxycodone  will be presented.   Concentrations will be listed and summarized 
by [CONTACT_591839].  
[IP_ADDRESS].2.  Derivation of Pharmacokinetic Parameters   
PK parameters will be derived from the concentration -time profiles as shown in Table  5. 
Table  5. Derivation of Pharmacokinetic Parame ters 
Parameter  Definition  Method of Determination  
Cmax Maximum plasma concentration  Observed  directly from data  
Tmax Time for C max Observed  directly from data as time 
of first occurrence  
AUC last Area under the plasma concentration -time 
profile from tim e zero to the time of  the last 
quantifiable concentration  (Clast) Linear /Log  trapezoidal method  
AUC infa Area under the plasma concentration -time 
profile  from time zero extrapolated to 
infinity time AUC last + (Clast*/k el), 
where  Clast* is the predicted  plasma  
concentration  at the last 
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 58  
 quantifiable  time point  estimated  
from  the log-linear  regression  
analysis.  
AUC 1 Area under the plasma concentration -time 
profile from time zero to 1 hour postdose  Linear/Log trapez oidal method  
AUC 2 Area under the plasma concentration -time 
profile from time zero to 2 hour s postdose  Linear/Log trapezoidal method  
AUC 3 Area under the plasma concentration -time 
profile from time zero to 3 hour s postdose  Linear/Log trapezoidal method  
AUC4 Area under the plasma concentration -time 
profile from time zero to 4 hour s postdose  Linear/Log trapezoidal method  
AUC 8 Area under the plasma concentration -time 
profile from time zero to 8 hour s postdose  Linear/Log trapezoidal method  
t1/2a Terminal elimination half -life Log e(2)/k el, 
where  kel is the terminal  phase  rate 
constant  calculated  by a linear  
regression  of the log-linear  
concentration -time curve.   Only  
those  data points  judged  to describe  
the terminal  log-linear  decline  will 
be used in the regression . 
a. If data permit.  
9.4.4.  Efficacy Analyses  
An efficacy analysis is not applicable to this study.  
9.4.5.  Safety Analyses  
All safety analyses will be performed on the safety population.  
The safety data will be described  and summarized in accordance with the sponsor’s Data 
Standards.  
AEs, ECGs, BP, pulse rate , RR, SpO 2 continuous cardiac monitoring, and safety laboratory 
data will be reviewed and summarized on an ongoing basis during the study to evaluate the 
safety of participant s.  Any clinical laborator y, ECG, BP, and pulse rate  abnormalities of 
potential clinical concern will be described.  Safety data will be presented in tabular and/or 
graphical format and summarized descriptively, where appropriate.  
PF-[ADDRESS_1090800] findings 
ident ified on physical and/or neurologic al examination s conducted during the active 
collection period  will be captured as AEs, if those findings meet the definition of an AE.  
Data collected at screening that are used for inclusion/exclusion criteria, such as l aboratory 
data, ECGs , and vital sig ns, will be considered source data, and will not be required to be 
reported , unless otherwise noted.  Demographic data collected at screening will be reported.  
[IP_ADDRESS].  Electrocardiogram Analyses  
Electrocardio gram  results collecte d at Screening will be listed.  
9.4.6.  Expl oratory Analyses  
Exploratory analysis will be conducted to evaluate the c orrelation between gabapentin  
concentrations and selected PD endpoints (Bipolar VAS for “Drug Liking”, Unipolar VAS 
for “High”, pupil diameter) in t he presence and absence of oxycodone, as data permit . 
9.5. Interim Analyses  
No formal interim analysis wil l be conducted for this study.  
9.6. Data Monitoring Committee  
This study will not use a data monitoring committee (DMC).  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 60  
 10. SUPPORTING DOCUMENTATION AND OPERATION AL CONSIDERATIONS  
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations  
10.1.1.  Regulatory  and Ethical Considerations  
This study will be conducted in accordance with the protocol and with the following:  
• Consensus ethical principles derived from inter national guidelines including the 
Declaration of Helsinki and Council for International Organiza tions of Medical 
Sciences (CIOMS) International Ethical Guidelines ; 
• Applicable International Council for Harmonisation (ICH)  Good Clinical Practice 
(GCP) guidel ines; 
• Applicable laws and regulations , including applicable privacy laws . 
The protocol, protocol amendments, IC D, investigator’s brochure ( IB), and other relevant 
documents (eg, advertisements) must be reviewed and approved by [CONTACT_791290]/EC by [CONTACT_22843]/EC 
before the study i s initiated.  
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary to elim inate an immediate 
hazard to study participants.  
The investigator will be responsible fo r the following:  
• Providing written summaries of the status of the study to the IRB/EC annually or 
more frequently in accordance with the requirements, policies, and pro cedures 
established by [CONTACT_1201]/EC ; 
• Notifying the IRB/EC of SAEs or other significant saf ety findings as required by 
[CONTACT_1744]/EC procedures ; 
• Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 Code of Federal Regulatio ns (CFR ), ICH guidelines, the IRB/EC, 
European regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulations . 
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 61  
 [IP_ADDRESS].  Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP  
In the event of any prohibition or restriction imposed (ie, clinical hold) by [CONTACT_22844], or if the investigator is aware of any new 
information that might influence the evaluation of the benefits and risks of the investigational 
product, Sponsor  should be informed immediately .   
In addition, the investigator will inform Spon sor immediately of any urgent safety measures 
taken by [CONTACT_791291] s against any immediate hazard, and 
of any serious breaches of t his protocol or of ICH GCP that the investigator becomes aware 
of. 
10.1.2.  Financial Disclosure  
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and acc urate financial 
certification or disclosure statements to the appropriate regulatory aut horities.  Investigators 
are responsible for providing information on financial interests during the course of the study 
and for 1 year after completion of the study.  
10.1.3.  Informed Consent Process  
The investigator or his/her representative will explain the nature of the study to the 
participant and answer all questions regarding the study.  
Participants must be informed that their participation is voluntary.  Participants will  be 
required to sign a statement of informed consent that meets the requirements of [ADDRESS_1090801] 
(HIPAA) requirements, where applicable, and the IRB/EC or study center.  
The investigator must ensure that each study participant  is fully informed about the n ature 
and objectives of the study, the sharing of data related to the study , and possible risks 
associated with participation, including the risks associated with the proce ssing of the 
participant ’s personal data.  
The participant must be informed that his/her personal study -related data will be used by [CONTACT_20004].  The level of disclosure must also be 
explained to the participan t. 
The participant must be informed that his/her medical records may be examined by [CONTACT_11000], by 
[CONTACT_6667]/EC members, and by [CONTACT_6668].  
The investigator further must ensure that each study participant  is fully informed about his or 
her right to access and correct his or her personal data and to withdraw consent for the 
processing of his or her personal data.  
PF-[ADDRESS_1090802] current version of the IC D(s) during their 
participation in the study.  
A copy of the IC D(s) must be provided to the participant.  
A participant who is rescreened is not required to sign another ICD if the rescreening occurs 
within  28 days f rom the previous ICD signature [CONTACT_568].  
10.1.4.  Data Protection  
All parties will comply with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant  data.  
Participants’ personal dat a will be stored at the study site in encrypted elect ronic form and 
will be  password protected  to ensure that only authorized study staff have access.  The study 
site will implement appropriate technical and organizational measures to ensure that the 
perso nal data can be recovered in the event of disaster.  In the event of a potential personal 
data breach, the study site shall be responsible for determining whether a personal data 
breach has in fact occurred and, if so, providing breach notifications as req uired by [CONTACT_2371].  
To protect the rights and freedoms of n atural persons with regard to the processing of 
personal data, participants will be assigned a single, participant -specific numerical code.  
Any participant records or data  sets that are transferred to t he sponsor will contain the 
numerical code; participa nt names will not be transferred.  All other identifiable data 
transferred to the sponsor will be identified by [CONTACT_20007], participant -specific code.  The 
study site will maintain a confidential list o f participant s who participated in the study, 
linking  each participant ’s numerical code to his or her actual identity.  In case of data 
transfer, the sponsor will protect the confidentiality of participant s’ personal data consistent 
with the clinical study agreement and applicable privacy laws.  
10.1.5.  Dissemination  of Clinical Study Data  
Upjohn  fulfills its commitment to publicly disclose clinical study results through posting the 
results of studies on www.clinicaltrials.gov  (ClinicalTrials.gov), the European Clin ical Trials 
Database (EudraCT), and other public registries in accordance with applicable local 
laws/regulations.  In addition, Upjohn  reports study results outside of the requirements of 
local laws/regulations pursu ant to its standard operating procedures  (SOPs).  
In all cases, study results are reported by [CONTACT_791292], accurate, balanced, and 
complete manner and are reported regardless of the outcome of the study or the country in 
which the study was condu cted.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 63  
 www.clinicaltrials.gov  
Upjohn  posts clinical trial US Basic Results on www.clinicaltrials.gov for Upjohn -sponsored 
interventional studies (conducted in patients) that evaluate the safety and/or efficacy of a 
product, regardless of the geographical lo cation in which the study is conducted.   
EudraCT  
Upjohn  posts European Union (EU) Basic Results on EudraCT for all Upjohn -sponsored 
interventional studies that are in scope of EU requirements.  EU Basic Results are submitted 
for posting within 1 year of t he PCD for studies in adult populations or within 6 months of 
the PCD for studies in pediatric populations.  
Documents within marketing authorization packages/submissions  
Upjohn  complies with the European Union Policy 0070, the proactive publication of clin ical 
data to the European Medicines Agen cy (EMA) website.   Clinical data, under Phase 1 of this 
policy , includes clinical overviews, clinical summaries, C SRs, and appendices containing the 
protocol and protocol amendments, sample CRF s, and statistical methods.  Clinical data, 
under Phase 2 of th is policy , includes the publishing of individual participant  data.  Policy 
0070 applies to new marketing authorization applications submitted via the centrali zed 
procedure since 01 January  2015 and applications for line extensions and for new indications 
submitted via the centralized procedure since 01 July 2015.  
Data Sharing  
Upjohn  provides researchers secure access to patient -level data or full CSRs for the purposes 
of “bona -fide scientific research” that contribute to the scientific understanding of the 
disease, target, or compound class.   Upjohn  will make available data from these trials 
[ADDRESS_1090803], including individuals 
requesting access for commercial/competitive or legal purposes.  
10.1.6.  Data Quality Assurance  
All participant d ata relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor o r designee electronically (eg, laboratory data).  The investigator is 
responsible for verifying that data entries are accurate and correct by [CONTACT_791293].  
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.  
PF-[ADDRESS_1090804] parties.  
The investigator mus t permit study -related monitoring, audits, IRB/EC review, and 
regulatory agency inspections and provide direct access to source data documents.   This 
verification may also occur after study completion.  It is important that the investigator(s) 
and their re levant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.  
Monitoring details describing strategy (eg, risk -based initiatives in operations and quality 
such as risk management and mitigation strategies and analytical risk-based monitoring), 
methods, responsibilities , and requirements, including handling of noncompliance issues and 
monitoring techniques (central, remote, or on -site monitoring) , are provided in the 
monitor ing plan . 
The sponsor or designee is responsible for the data management of this study , including 
quality checking of the data.  
Study monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by [CONTACT_205754], complete, and verifiable from source 
documents; that the safety and rights of par ticipants are being protected; and that the study is 
being conducted in accordance with the currently approved protocol and any other study 
agreements, ICH G CP, and all applicable regulatory requirements.  
Records and documents, including signed IC Ds, perta ining to the conduct of this study must 
be retained by [CONTACT_1732] [ADDRESS_1090805] ensure that the records continue to be stored securely for as long as they are 
maintaine d. 
When participant  data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_306891].  
The investigator(s) will notify the sponsor or its agents immediately of any regulatory 
inspection notification in rel ation to the study.  Furthermore, the investigator will cooperate 
with the sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection.  The 
inves tigator site and investigator will promptly resolve any discrepancies that are identified 
between the study data and the participant's med ical records.  The investigator will promptly 
provide copi[INVESTIGATOR_19946].  Before response 
submission to the regulatory authorities, the investigator will provide the sponsor or its 
agents with an opportunity to r eview and comment on responses to any such findings.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 65  
 10.1.7.  Source Documents  
Source documents provide evidence for the existe nce of the participant and substantiate the 
integrity of the data collected.   Source documents  are filed at the investigator  site. 
Data re ported on the CRF or entered in the electronic CRF ( eCRF ) that are transcribed from 
source documents must be consisten t with the source documents or the discrepancies must be 
explained .  The investigator may need to request previous medical records or tran sfer 
records, depending on the study.  Also, current medical records must be available.  
Definition of what constitutes  source data can be found in the Clinical Monitoring Plan.  
10.1.8.  Study and Site Closure  
The sponsor designee reserves the right to close the stu dy site or terminate the study at any 
time for any reason at the sole discretion of the sponsor.   Study sites will be closed upon 
study completion.  A study site is considered closed when all required documents and study 
supplies have been collected and a study -site closure visit has been performed.  
The investigator may initiate study -site closure at any time  upon notification to the sponsor if 
requested to do so by [CONTACT_22846]/EC or if such termination is required to protect the 
health of study par ticipants . 
Reasons for the early closure of a study site by [CONTACT_19711]: 
• Failure of the investigator to comply with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or GC P guidelines ; 
• Inadequate recruitment of participants by [CONTACT_093] ; 
• Discontinuation of further study  intervention development . 
Study termination is also provided for in the clinical study agreement.  If there is any conflict 
between the contract and this protocol , the contract will control as to termination rights.  
10.1.9.  Publication Policy  
The results of this study may be published or presented at scientific meetings by [CONTACT_22847] 1 year after end of t he study (or 
study termination), whichever comes first.  
The investigator agrees to re fer to the primary publication in any subsequent publications 
such as secondary manuscripts , and submit s all manuscripts or abstracts to the sponsor 
[ADDRESS_1090806] y. 
10.1.10.  Sponsor’s Qualified Medical Personnel  
The contact [CONTACT_1133]'s appropriately qualified medical personnel for the 
study is documented in the  study contact [CONTACT_791294] .  
To facilitate access to appropriately q ualified medical personnel on study -related medical 
questions or problems , participant s are provided with a contact [CONTACT_1137].  The contact [CONTACT_95504], at a minimum, protocol and investigational product identifiers, participant  numbers, 
contact [CONTACT_3031] f or the investigator site, and contact [CONTACT_4664] a contact [CONTACT_791295] a medical 
question or problem originating from another healthcare professional not involved in the 
participant ’s participation in the study.  The contact [CONTACT_791296]; however, it should be used 
only in the event that the established communication pathways between th e investigator site 
and the study team are not available.  It is therefor e intended to augment, but not replace, the 
established communication pathways between the investigator site and the study team for 
advice on medical questions or problems that may ar ise during the study.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 67  
 10.2. Appendix 2:  Clinical Laboratory Tests  
The following safety laboratory tests (Table  6) will be performed at times defined in the 
Schedule of Activities  (SoA) .  Additional laboratory results may be reported on these 
samples as a result of the method of analysis or the type of analyzer used by [CONTACT_332854]; or as derived from calculated values.  These additional tests would not requi re 
additional collection of blood.  Unscheduled clinica l laboratory measurements may be 
obtained at any time during the study to assess any perceived safety concerns.  
Table  6. Laboratory Tests  
Hematology  Chemistry  Urinalysis  Other  
Hemoglobin  
Hematocrit  
RBC count  
MCV  
MCH  
MCHC  
Platelet count  
WBC count  
Total neutrophils (Abs)  
Eosinophils (Abs)  
Monocytes (Abs)  
Basophils (Abs)  
Lymphocytes (Abs)  BUN/urea and 
creatinine  
Glucose (fasting)  
Calcium  
Sodium  
Potassium  
Chloride  
Total CO 2 (bicarbonate)  
AST, ALT  
Total bilirubin  
Alkaline phosphatase  
Uric acid  
Albumin  
Total protein  pH 
Glucose (qual)  
Protein (qual)  
Blood (qual)  
Ketones  
Nitrites  
Leukocyte esterase  
Urobilinogen  
Urine bilirubin  
Microscopya FSHb 
Urine drug  screeningc 
Alcohol breatha lyzer or 
urine  
β-hCGd 
Hepatitis B surface 
antigen  
Hepatitis B core 
antibody  
Hepatitis C core 
antibody  
Human 
immunodeficiency virus  
 Additio nal Tests 
(Needed for Hy’s Law)   HAV IgM  
HAV IgG  
 AST, ALT (repeat)  
Total bilirubin (repeat)  
Albumin (repeat)  
Alkaline phosphatase 
(repeat)  
Direct bilirubin  
Indirect bilirubin  
Creatine kinase  
GGT  
PT/INR  
Total bile acids  
Acetaminophen drug 
and/or protein a dduct 
levels    
Abbreviations: Ab s = absolute; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
β-hCG = beta -human chorionic gonadotropin; BUN = blood urea nitr ogen; CO 2 = carbon dioxide;  
FSH = follicle -stimulating hormone; MCH = mean corpuscular hemoglobin; MCHC = mean corpus cular 
hemoglobin concentration;  MCV = mean corpuscular volume; qual = qual itative; RBC = red blood cell; 
WBC = white blood cell.  
a. Only if urine dipstick is positive for blood, protein, nitrites or leukocyte esterase . 
b. For confirmation  of postmenopausal status only.  
c. The minimum requirement for drug screening includes cocaine, tetr ahydrocannabinol (THC), opi[INVESTIGATOR_858]/opi[INVESTIGATOR_2438], 
benzodiazepi[INVESTIGATOR_1651], and amphetamines (others are site and study specific).  
d. Serum or urine β -hCG for female participant s of childbearing potential.  
PF-[ADDRESS_1090807] document their review of each laboratory safety report.  
Laboratory/analyte results that could unblind the study will not be reported to investigator 
sites or other blinded personnel until the study has been unblinded.  
Any remaining serum/plasma from samples collected for clinical safety lab oratory 
measurements  at baseline and at all times after dose administration  may be retained and 
stored for the duration of the st udy.  Upon completion of the study, these retained safety 
samples may be used for the assessment of exploratory safety biomarkers  or unexpected 
safety findings .  These data will no t be included in the CSR .  Samples to be used for this 
purpose will be shipp ed to either a Upjohn -approved Biospecimen Banking System (BBS) 
facility or other designated laboratory and  retained for up to 1 year following the completion 
of the study.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 69  
 10.3. Appendi x 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, F ollow -up, and Reporting  
10.3.1.  Definition of AE  
AE Definition  
An AE is any untoward medical occurrence in a patient or clinical study participant, 
temporally associated with the use of study intervention, whether or not considered 
related to the study interventi on. 
NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated wit h the use of study intervention.  
 
Events Meeting  the AE Definition  
• Any abno rmal laboratory test results (hematology, clinical chemistry, or 
urinalysis) or other safety assessments (eg, ECG, radiological scans, vital sign 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and  scientific judgment of the investigator (ie, not 
related to progression of underlying disease).  
• Exacerbation of a chronic or intermittent preexisting condition including either 
an increase in frequency and/or intensity of the condition.  
• New conditions det ected or diagnosed after study intervention administration 
even though it may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of  a suspected drug -drug interaction.  
• Signs, symptoms, or the clinical sequelae of a su spected overdose of either study 
intervention or a concomitant medication.  Overdose per se will not be reported 
as an AE/SAE unless it is an intentional overdose taken wi th possible 
suicidal/self -harming intent.  Such overdoses should be r eported regardle ss of 
sequelae.  
 
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 70  
 Events NOT  Meeting the AE Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by 
[CONTACT_19448]’s condition.  
• The disease/disorder being studied or expected progression, signs, or symptoms 
of the disease/disorder being studied,  unless more severe than expected for the 
participant’s condition.  
• Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that 
leads to the procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social an d/or 
convenience admission to a hospi[INVESTIGATOR_307]).  
• Anticipated day -to-day fluctuations of preexisting dis ease(s) or condition(s) 
present or detected at the start of th e study that do not worsen.  
10.3.2.  Definition of SAE  
If an event is not an AE per definition above, the n it cannot be an SAE even if serious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death 
due to progression of disease).  
An SAE is defined as any untoward medical occurrence that, at any dose:  
a. Results in death  
b. Is life -threatening  
The term “life-threatening ” in the definition of “serious ” refers to an e vent in which the 
participant was at risk of death at the time of th e event.  It does not refer to an event that 
hypothetically might have caused death if it were more severe.  
c. Requires inpatient hospi[INVESTIGATOR_791256], hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay) at the hospi[INVESTIGATOR_12332]/or treatment that would not have been appropriate in the physician’s office  or 
outpatient setting.  Complications that occur during hospi[INVESTIGATOR_1084].  If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious.   When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was neces sary, the 
AE should be considered serious.  
Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen from 
baseline is not considered an AE.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 71  
 d. Results in persi stent disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  
• This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated hea dache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle) which may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
f. Other situatio ns: 
• Medical or scientific judgment should be exercised in deciding w hether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediately life -threatening or result in death or hospi[INVESTIGATOR_791257] t o 
prevent one of the other outcomes listed in the above definition.   These events 
should usually be considered serious.  
• Examples of such events include invasive or malignant cancers, inten sive 
treatment in an emergency room or at home for allergic bronchos pasm, blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059], or development of 
drug dependency or drug abuse.  
10.3.3.  Recording /Reporting and Follow -up of AE s and/or SAE s 
AE and SAE Recording /Reporting  
The table below summarizes the requirements for recording adverse events on the CRF 
and for reporting serious adverse events on the Clinical Trial (CT) Serious Adverse 
Event (SAE) Report Form to [COMPANY_007] Safety.  These requirements are delineated for 
3 types of events: (1)  SAEs; (2) nonserious adverse  events (AEs); and (3) exposure to 
the investigational product under study during pregnancy or breastfeeding, and 
occupational exposure.  
It should be noted t hat the CT SAE Report Form for reporting of SAE information is not 
the same as the AE page of the CRF.  When the same data are collected, the forms must 
be completed in a consistent manner.  AEs should be recorded using concise medical 
terminology and the same AE term should be used on both the CRF and the CT SAE 
Report Form for reporting of SAE inform ation.  
PF-[ADDRESS_1090808] 
under study during 
pregnancy or 
breastfeeding, and 
occupa tional exposure  None  All (and exposure during 
pregnancy [ EDP ] 
supplemental form for 
EDP)   
 
• When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory reports, and diagnostic 
reports) related to the event.  
• The investigator will then record all relevant AE/SAE information in the CRF.  
• It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Safety in lieu of completion of the CT S AE Report 
Form /AE/SAE CRF page.  
• There may be instances when copi[INVESTIGATOR_181863] d by [CONTACT_181889] .  In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_240803] . 
• The investigator will attempt to establish a diagnosis o f the event based on signs, 
symptoms, and/or other clinical information.  Whenever possible, the diagnosis 
(not the individual signs/symptom s) will be documented as the AE/SAE.  
Assessment of Intensity  
The investigator will make an assessment of intensity  for each AE and SAE reported 
during the study and assign it to 1 of the following categories:  
• Mild: An event that is easily tolerated by t he participant, causing minimal 
discomfort and not interfering with everyday activities.  
• Moderate: An event that cau ses sufficient discomfort and interferes with normal 
everyday activities.  
• Severe: An event that prevents normal everyday activities.  An AE that is 
assessed as severe should not be confused with a n SAE.   Severe is a category 
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 73  
 utilized for rating the intensity of an event; and both AEs and SAEs can be 
assessed as severe.  
An event is defined as “serious ” when it meets at least 1 of the predefined  
outcomes as described in the definition of an SAE, NOT when it is rated as 
severe.  
 
Assessment of Causality  
• The investigator is obligated to assess the relationship between study intervention 
and each occurrence of each AE/SAE.  
• A “reasonable possibility ” of a relationship conveys that there are facts, 
evidence, and/or arguments to suggest a causal relationship, rather than a 
relationship cannot be ruled out.  
• The investigator will use clinical judgment to determine the relationship.  
• Alternative causes, su ch as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal  relationship of the event to study intervention 
administration will be considered and investigated.  
• The investigator will also consult the investigator’s brochure (IB) and/or product 
information, for marketed products, in his/her assessment.  
• For each AE/S AE, the investigator must  document in the medical notes that 
he/she has reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situation s in which an SAE has occurred and the investigator has 
minimal information to include in the ini tial report to the sponsor .  However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial tran smission of the SAE data to the 
sponsor . 
• The investigator may change his/her opi[INVESTIGATOR_9242] -up 
information and send a n SAE follow -up report with the updated causality 
assessment.  
• The causality assessment is one of the criteria used  when determining regulatory 
reporting requirements.  
• If the investigator does not know w hether or not the investigational product 
caused the event, then the event will be handled as “related to investigational 
product” for reporting purposes, as defined by  [CONTACT_456] .  In addition, if the 
investigator determines that an SAE is associated wit h study procedures, the 
PF-[ADDRESS_1090809] SAE 
Report Form and in accordance with the SAE reporting requirements.  
 
Follow -up of AEs and SAEs  
• The investigator is obligated to perform or arrange for the conduct of 
supplemental measurements and/or evaluations as medically indicated or as 
request ed by [CONTACT_791297]/or causality of the AE or 
SAE as fully as possible.  This may include additional laboratory tests or 
investigations, histopathological examinations, or consultation with other 
healthcare professionals.  
• If a par ticipant dies during participation in the study or during a recognized 
follow -up period, the investigato r will provide [COMPANY_007] Safety with a copy of any 
postmortem fi ndings including histopathology.    
• New or updated information will be recorded in the origi nally completed CRF.  
• The investigator will submit any updated SAE data to the sponsor within 
24 hours of receipt of the information.  
10.3.4.  Reporting of SAEs  
SAE Reporting to [COMPANY_007] Safety  via an Electronic Data Collection Tool  
• The primary mechanism for reporti ng an SAE to [COMPANY_007] Safety  will be the 
electronic data collection tool.  
• If the electronic system is unavailable, then the site will use the paper SAE data 
collection tool ( see next section) in order to report the event within 24 hours.  
• The site will enter the SAE data into the electronic system as soon as the data  
become available.  
• After the study is completed at a given site, the electronic data collection tool 
will be taken off -line to prevent the entry of new data or changes to existing data.  
• If a site r eceives a report of a new SAE from a study participant or receives 
updated data  on a previously reported SAE after the electronic data collection 
tool has been taken off -line, then the site can report this information on a paper 
SAE form (see next section)  or to [COMPANY_007] Safety by [CONTACT_756].  
 
PF-[ADDRESS_1090810] SAE Report Form  
• Facsimile transmission of the CT SAE Report Form  is the preferred method to 
transmit this information to [COMPANY_007] Safety . 
• In circumstances when the facsimile is not w orking , notification by [CONTACT_20021] a copy of the CT SAE Report Form  sent by [CONTACT_20022].  
• Initial notification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages within the designated 
reporting time frames.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 76  
 10.4. Appendix 4:  Contraceptive Guidance and Collection of Pregnancy Information  
10.4.1.  Male Participant Reproductive Inclusion Criteria  
Male participants are eligible to participate if they agree to the following requ irements during 
the intervention period and for at least [ADDRESS_1090811] dose of study intervention , which 
corresponds to the time needed to eliminate study intervention(s)  plus an additional 90 days 
(a spermatogenesis cycle):  
• Refrain from donating  sperm . 
PLUS either : 
• Be abstinent from heterosexual  intercourse as their preferred and usual lifestyle 
(abstinent on a long -term and persistent basis) and agree to remain abstinent ;  
OR 
• Must agree to use contraception/barrier as detailed below :  
• Agree to use a male condom when engaging in any activity that allows for 
passage of ejaculate to another person . 
• Male participants should be advised of the benefit for a female partner to use a highly 
effective method of contraception , as a condom may break or leak when having 
sexual intercourse with a WOCBP  who is not currently pregnant . 
10.4.2.  Female Participant Reproduct ive Inclusion Criteria  
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at 
least 1 of the following condition s applies:  
• Is not a WOCBP (see definitions below  in Section 10.4.3 ); 
OR 
• Is a WOCBP and using a contraceptive method that is highly effective (with a failure 
rate of <1% per year), with low user de pendency, as described below , during the 
intervention period and for at least [ADDRESS_1090812] dose of study intervention , 
which corresponds to the t ime needed to eliminate any study intervention(s).   
• A WOCBP agrees not to donate eggs (ova, oocytes)  for the purpose of reproduction 
during this period.   The investigator should evaluate the effectiveness of the 
contraceptive method in relationship to the  first dose of study intervention.  
The investigator is responsible for review of medical history, men strual history, and recent 
sexual activity to decrease the risk for inclusion of a woman with an early undetected 
pregnancy.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 77  
 10.4.3.  Woman of Childbearing Potential (WOCBP)  
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanently sterile (see below).  
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot 
be co nfirmed before the first dose of study intervention, additional evaluation should be 
considered.  
Women in the following c ategories are not considered WOCBP:  
1. Premenopausal female with 1 of the following:  
• Documented hysterectomy;  
• Documented bilateral salpi[INVESTIGATOR_61502];  
• Documented bilateral oophorectomy.  
For individuals with permanent infertility due to an alternate medical cause o ther than 
the above,  (eg, mullerian agenesis, androgen insensitivity), investigator discretion 
should be applied to determining study e ntry. 
Note: Documentation for any of the above categories can come from the site 
personnel’s review of the participant’s medical records, medical examination, or 
medical history interview.   The method of documentation should be recorded in the 
participant’ s medical record for the study.  
2. Postmenopausal female . 
• A postmenopausal state is defined as age 60  years  or older or no m enses for 
12 months without an alternative medical cause.  
• A high follicle -stimulating hormone (FSH) level in the postmenopausal range 
may be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormon e replacement therapy (H RT).  
• Females on HRT and whose menopausal status is in doubt will be required to 
use one of the non hormonal highl y effective contraception methods.  
PF-[ADDRESS_1090813] Low User Dependency  
1. Intrauterine device (IUD) . 
2. Bilateral tubal occlusion . 
3. Vasectomized  partner . 
• Vasectomized partner is a highly effective contraceptive method provided that the 
partner is the sole sexual partner of the woman of childbearing potential and the 
absence of sperm has been confirmed.  If not,  an additional highly effective 
method of contraception should be used.   The s permatogenesis cycle is 
approximately 90 days.  
Collection of Pregnancy Information  
For both unapproved/unlicensed products and for marketed products, an exposure during 
pregnancy  (EDP) occurs if:  
• A female becomes, or is found to be, pregnant either while receiving or having been 
exposed (eg, because of treatment or environmental exposure) to the investigational 
product; or the female becomes or is found to be pregnant after discon tinuing and/or 
being exposed to the invest igational product;  
• An example of environmental exposure would be a case involving direct contact 
[CONTACT_4490] a [COMPANY_007] product in a pregnant woman (eg, a nurse reports that she is pregnant 
and has been exposed to chemother apeutic products).  
• A male has been exposed  (eg, because of treatment or environmental exposure) to the 
investigational product prior to or around the time of conception and/or is exposed 
during his partner’s pregnancy.  
If a participant  or participant ’s par tner becomes or is found to be pregnant du ring the 
participant ’s treatment with the investigational product, the investigator must report this 
information to [COMPANY_007] Safety on the CT SAE Report Form and an EDP supplemental form, 
regardless of whether an SAE  has occurred.   In addition, the investiga tor must submit 
information regarding environmental exposure to a [COMPANY_007] product in a pregnant woman (eg, a 
participant  reports that she is pregnant and has been exposed to a cytotoxic product by 
[CONTACT_177278]) to [COMPANY_007] Safety using the EDP suppl emental form.  This must be done 
irrespective of whether an AE has occurred and within 24  hours of awareness of the 
exposure.  The information submitted should include the anticipated date of delivery (see 
below fo r information related to termination of pr egnancy).  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 79  
 Follow -up is conducted to obtain general information on the pregnancy and its outcome for 
all EDP reports with an unknown outcome.  The investigator will follow the pregnancy until 
completion (or until pr egnancy termination) and notify [COMPANY_007] Saf ety of the outcome as a 
follow -up to the initial EDP supplemental form.  In the case of a live birth, the structural 
integrity of the neonate can be assessed at the time of birth.  In the event of a termination, th e 
reason(s) for termination should be spec ified and, if clinically possible, the structural 
integrity of the terminated fetus should be assessed by [CONTACT_4692] (unless 
preprocedure test findings are conclusive for a congenital anomaly and the f indings are 
reported).  
If the outcome of t he pregnancy meets the criteria for an SAE (ie, ectopic pregnancy, 
spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomaly [in a 
live-born baby, a terminated fetus, an intrauterine fe tal demise, or a neonatal death]), the 
investigator should follow the procedures for reporting SAEs.  
Additional information about pregnancy outcomes that are reported to [COMPANY_007] Safety as SAEs 
follows:  
• Spontaneous abortion includes miscarriage and missed a bortion;  
• Neonatal deaths that occur within  [ADDRESS_1090814].  
Additional information regarding the EDP may be requested by [CONTACT_456].  Further 
follow -up of birth outcomes will be handled on a case -by-case basis (eg, follow -up on 
preterm infants to identify deve lopmental delays).  In the case of paterna l exposure, the 
investigator will provide the participant  with the Pregnant Partner Release of Information 
Form to deliver to his partner.  The investigator must document in the source documents that 
the participan t was given the Pregnant Partner Release o f Information Form to provide to his 
partner.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 80  
 10.5. Appendix 5: Genetics  
Use/Analysis of DNA  
• Genetic variation may impact a participant’s response to study intervention, 
susceptibility to, and severity and progression of  disease.  Therefore, where local 
regulations and IRBs/ECs allow, a blood sample will be collected for DNA analysis.  
• Genetic research may consist of the analysis of 1 or more candidate genes or the 
analysis of genetic markers throughout the genome (as appr opriate).  
• The samples may be analy zed as part of a multistudy assessment of genetic factors 
involved in the response to gabapentin and oxycodone  or study interventions of this 
class to understand treatments for the disease(s) under study or the disease(s) 
themselves.  
• The results of genetic analyses may be reported in the clinical study report (CSR) or 
in a separate study summary, or may be used for internal decision making without 
being included in a study report.  
• The sponsor will store the DNA samples in a  secure storage space with adequate 
measures to protect confidentiality.  
• The samples will be retained as indicated:  
• Samples for banking (see Section 8.7.2 ) will be stored indefinitely or other pe riod 
as per local requirements.   
• Participants may withdraw their consent for the storage and/or use of their banked 
biospecimens at any time by [CONTACT_7328] a request to the investigator; in this case, any 
remaining material will be destroyed.  Data already gen erated from the samples will 
be retained to protect the integrity of existing analyses.   
Banked biospecimens will be labeled with a code.  The key between the code and the 
participant’s personally identifying informatio n (eg, name, address) will be held a t the study 
site and will not be provided to the sample bank . 
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 81  
 10.6. Appendix 6: Liver Safety: Suggested Actions and Follow -up Assessments  
Potential Cases of Drug -Induced Liver Injury  
Humans exposed to a drug who show no sign of liver injury (as determined by [CONTACT_791298]) are termed “tolerators,” while those who show transient liver injury, but adapt 
are termed “adaptors.”  In some participant s, transaminase elevations a re a harbinger of a 
more serious potential outcome.  These participant s fail to  adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonly referred to as drug -induced 
liver injury (DILI).  Participant s who experience a transami nase elevation above 3  times the 
upper limit of normal ( × ULN) should be monito red more frequently to determine if they are 
an “adaptor” or are “susceptible.”  
Liver function tests ( LFTs) results should be managed and followed as described below.  
In the maj ority of DILI cases, elevations in aspartate aminotransferase (AST) and/or alan ine 
aminotransferase (ALT) precede total bilirubin (TBili) elevations (>2 × ULN) by [CONTACT_74097].  The increase in TBili typi[INVESTIGATOR_161651]/ALT is/are still ele vated 
above 3 × ULN (ie, AST/ALT and TBili values will be elevated within the s ame lab oratory  
sample).  In rare instances, by [CONTACT_22858], AST/ALT values might 
have decreased.  This occurrence is still regarded as a potential DIL I.  Therefore, abnormal 
elevations in either AST OR ALT in addition to TBili th at meet the criteria outlined below 
are considered potential DILI (assessed per Hy’s law criteria) cases  and should always be 
considered important medical events, even before al l other possible causes of liver injury 
have been excluded.  
The threshold of la boratory abnormalities for a potential DILI case depends on the 
participant ’s individual baseline values and underlying conditions.  Participant s who present 
with the following laboratory abnormalities should be evaluated further as potential DILI 
(Hy’s la w) cases to definitively determine the etiology of the abnormal laboratory values:  
• Participant s with AST/ALT and TBili  baseline values within the normal range who 
subsequently p resent with AST OR ALT values >3 × ULN AND a TBili value 
>2 × ULN with no evide nce of hemolysis and an alkaline phosphatase value 
<2 × ULN or not available.  
• For participant s with baseline AST OR ALT OR TBili  values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:  
• Preexisting AST or ALT baseline values above the normal range:  AST or ALT 
values >2  times the baseline values AND >3 × ULN; or >8  × ULN (whichever is 
smaller).  
• Preexisting values of TBili above the normal range: TBili level increased from 
baseline value by [CONTACT_8895] 1 × ULN or if the value reaches 
>3 × ULN (whichever is smaller).  
PF-[ADDRESS_1090815]/ALT and TBili separated by [CONTACT_726] a few weeks should be assessed 
individually based on clinical judgment; any case  where uncertainty remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.   
The participant  should return to the investigator site and be evaluated as soon as possible, 
preferably within [ADDRESS_1090816] and ALT and TBili  for suspected cases of 
Hy’s law, additional laboratory tests should include a lbumin, creatine kinase (CK), direct and 
indirect bilirubin, gamma -glutamyl transferase (GGT), prothrombin time (PT)/internation al 
normalized ratio (INR), total bile acids, and alkaline phosphatase.  Consideration should also 
be given to drawing a separate  tube of clotted blood and an anticoagulated tube of blood for 
further testing, as needed, for further contemporaneous analyses at the time of the recognized 
initial abnormalities to determine etiology.  A detailed history, including relevant 
information, such as review of ethanol, acetaminophen (either by [CONTACT_20025] a coformulated 
product in prescription or over -the-counter medi cations) , recreational drug, supplement 
(herbal) use and consumption, family history, sexual history, travel history, history of  contact 
[CONTACT_4490] a jaundiced person, surgery, blood transfusion, history of liver or allergic disease, and 
potential occupational e xposure to chemicals, should be collected.  Further testing for acute 
hepatitis  A, B, C, D, and E infection and liver imaging (e g, biliary tract) and collection of 
serum sample for acetaminophen drug and/or protein adduct levels may be warranted.  
All case s demonstrated on repeat testing as meeting the laboratory criteria of AST/ALT and 
TBili elevation defined above should be consi dered potential DILI (Hy’s law) cases if no 
other reason for the liver function test ( LFT) abnormalities has yet been found.  Such 
potential DILI (Hy’s law) cases are to be reported as SAEs, irrespective of availability 
of all the results of the investigat ions performed to determine etiology of the LFT 
abnormalities.   
A potential DILI (Hy’s law ) case becomes a confirmed case only after all results of 
reasonable investigations have been received and have excluded an alternative etiology.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 83  
 10.7. Appendix 7: ECG Find ings of Potential Clinical Concern  
ECG Findings That May Qualify as Adverse Events  (AEs) 
• Marked sinus bradycardia (rate <40 bpm)  lasting minutes . 
• New PR interval prolongation >280 ms ec. 
• New prolongation of QTcF to >480 ms ec (absolute) or by 60 msec from 
baseline . 
• New -onset atrial flutter or fibrillation, with controlled  ventricular response  rate: 
ie, rate <120 bpm . 
• New -onset type I second -degree (Wenckebach) AV block of >30 seconds ’ 
duration . 
• Frequent premature ventricular complexes (PVCs),  triplets , or short intervals 
(<30  seconds) of consecutive ventricular complexes . 
ECG Findings That May Qualify as Serious Adverse Events  (SAE s) 
• QTcF prolongation >500 ms ec. 
• New ST -T changes suggestive of myocardial  ischemia . 
• New -onset left bundle branch block (QRS  >120 ms ec). 
• New -onset right bundle branch block (QRS  >120 ms ec). 
• Symptomatic bradycardia .  
• Asystole:  
• In awake, symptom -free participant s in sinus rhythm, with documented 
periods of asystole 3.0 seconds or any escape rate <40 bpm, or with an 
escape rhythm tha t is below the AV node.  
• In awake, symptom -free participant s with atrial fibrillation  and bradycardia 
with [ADDRESS_1090817] 5 seconds or longer.  
• Atrial flutter or fibrillation , with rapid ventricular response rate:  rapid = rate 
>120  bpm. 
• Susta ined supraventricular tachycardia (rate >120 bpm)  (“sustained ” = short 
duration  with relevant symptoms or lasting >1 minute) . 
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 84  
 • Ventricular r hythms >30 seconds ’ duration, including idioventr icular rhythm (rate 
<40 bpm), accelerated idioventricular rhythm (40 < x <100) , and 
monomorphic/polymorphic  ventricular tachycardia >100 bpm (such as  torsades 
de pointes) . 
• Type II second -degree  (Mobitz  II) AV block. 
• Complete (third -degree) heart block. 
ECG Findings That Qualify as Serious Adverse Events  
• Change in pattern suggestive of new myocardial infarction .  
• Sustained ventricular tachyarrhythmias (>30 seconds ’ duration) . 
• Second - or third -degree AV block requiring pacemaker placement . 
• Asystolic pauses requiring pacemaker placement . 
• Atrial flutter or fibrillation with ra pid ventricular response requiring 
cardioversion . 
• Ventricular fibrillation/ flutter . 
• At the discretion of the investigator, any arrhythmia classified as an adverse 
experience . 
The enumerated list of major events of potential clinical concern are recommende d as “alerts ” or 
notifications from the core ECG lab oratory  to the investigator and Upjohn  study team , and not to be 
considered as all  inclusive  of what to be reported as AEs/SAEs.  
 
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 85  
 10.8. Appendix 8: Clinical Opi[INVESTIGATOR_791258], circle the numb er that best describes the patient' s signs or symptom.  Rate on 
just the apparent relationship to opi[INVESTIGATOR_2533].  For example, if heart rat e is increased 
because the patient was jogging just prior to assessment, the increase pulse rate would not 
add t o the score.  
Patient' s Name:  [CONTACT_33504]:  
Reason for this assessment:  
Resting Pulse Rate:  beats/minute  
Measured after patient is sitting or lying for one  
minute  
0 pulse rate 80 or below  
1 pulse rate 81 -100  
2 pulse rate 101 -120  
4 pulse rate great er than 120  GI Upset:  over last 1/2 hour  
0 no GI symptoms  
1 stomach cramps  
2 nausea or loose stool  
3 vomiting or diarrhea  
5 multiple epi[INVESTIGATOR_791259]:  over past 1/2 hour not accounted for 
by [CONTACT_791299].  
0 no report of chills or flushing  
1 subjective report of chills or flushing  
2 flushed or observa ble moistness on face  
3 beads of sweat on brow or face  
4 sweat streaming off face  Tremor  observation of outstretched 
hands  
0 no tremor  
1 tremor can b e felt, but not observed  
2 slight tremor observable  
4 gross tremor or muscle twitching  
Restlessness  Observation during assessment  
0 able to sit still  
1 reports difficulty sitting still, but is able to do 
so  
3 frequent shifting or extraneous movements  of 
legs/arms  
5 unable to sit still for more than a few seconds  Yawning  Observation during 
assessment  
0 no yawning  
1 yawning once or twice during 
assessment  
2 yawning three or more times during 
assessment  
4 yawning several times/minute  
Pupil size   
0 pupi[INVESTIGATOR_2658]  
1 pupi[INVESTIGATOR_791260]  
2 pupi[INVESTIGATOR_2660]  
5 pupi[INVESTIGATOR_791261]   
0 none  
1 patient reports increasing irrita bility 
or anxiousness  
2 patient obviously irritable or anxious  
4 patient so irritable or anxious that 
participation in the assessment is 
difficult  
Bone or Joint aches  if patient was having pain 
previously, only the additional component 
attributed to opi [INVESTIGATOR_182076]  
0 not present  
1 mild diffuse discomfort   
2 patient reports severe diffuse aching of 
joints/muscles  Gooseflesh skin  
[ADDRESS_1090818] eyes  
2 nose running or tearing  
4 nose con stantly running or tears streaming 
down cheeks  Total Score ________ __ 
 
The total score is the sum of all 
11 items  
 
Initials of person completing 
assessment: ______  
Score: 5 - 12 = mild; 1 3 -24 = moderate; 25 -36 = moderately severe; more than 36 = severe 
withdrawal . 
 
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 87  
 10.9. Appendix 9: VAS Assessment Methods  
The overall appearance of all VAS items utilizing the  Cambridge Neuropsychological Test 
Automated Battery  (CANTAB ) or using comparable software  will be  similar to screen 
images shown below.  The participant s will be trained to use the software at the site . 
Image A: sc reen display of Drug Liking VAS  
 
The questions and anchors on VAS items will be modified appropriately to reflect study 
specific questions as shown in Images B -D (Table  7). 

PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 88  
 CANTAB  
Image B: screen display of High VAS  
 

PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 89  
 Image C: screen display of Overall Drug Liking VAS  
 

PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 90  
 Image D: screen display of Take Drug Again VAS  
 
Table  7. Other Subjective Effects Visual Analog Scales  
SCALE DESCRIPTION  STATEMENT  TEXT  RESPONSE ANCHORS  
Good Drug Effects  At this moment, I can feel 
good drug effects  
0: Not at all  
100: Extremely  Bad Drug Effects  At this moment, I can feel 
bad drug effects  
Feeling Sick  At this moment, I am feeling 
sick 
Nausea  At this moment, I am feeling 
nausea  
Any Drug Effects  At this moment, I can feel 
any drug effect  
Sleepy  At this moment, I am feeling 
sleepy  
Dizzy  At this moment, I am feeling 
dizzy  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 91  
 10.10.  Appendix 10 : Alternative Measures During Public Emergencies  
The alternative study measur es described in this section  are to be  followed  during  public 
emergencies, including the COVID -19 pandemic.  This appendix applies for  the duration of 
the COVID -19 pandemic globally and will become effective for othe r public emergencies 
only upon written n otification from Upjohn .  
Use of these alternative study measures are expected to cease upon the return of business as 
usual circumstances (including the lifting of any quarantines and travel bans/advisories).  
10.10.1.  Eligibility  
Not applicable . 
10.10.2.  Telehealth Visits   
Not applicable .  
10.10.3.  Alternative Facilities for Safety Assessments    
Not applicable . 
10.10.4.  Study Intervention   
If the safety of a trial participant is at risk because they cannot complete required evaluations 
or adhere to critical mitigation steps, then discontinu ing that participant from study 
intervention must be considered.  
10.10.5.  Home Health Visits   
Not applicable . 
10.10.6.  Adverse Events and Serious Adverse Events  
If a participant has COVID -19 during the study, this should b e reported as an adverse event 
(AE) or serious adver se events (SAE) and appropriate medical intervention provided.  
It is recommended that the investigator discuss temporary or permanent discontinuation of 
study intervention with the study medical monitor.   
10.10.7.  Efficacy Assessments  
Not applicable . 
10.10.8.  Independent O versight Committees  
Not applicable . 
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 92  
 10.11.  Appendix 11: Abbreviations  
The following is a list of abbreviations that may be used in the protocol.   
Abbreviation  Term  
Abs Absolute  
ACLS  advanced cardiac life support  
AE adverse event  
ALT  alanine aminotransferase  
ANOVA  Analysis of variance  
AST  aspartate aminotransferase  
AUC  area under the curve  
AUEC  area under the effect curve  
AV atrioventricular  
BBB  blood –brain barrier  
BBS  Biospecimen Banking System  
-hCG  beta-human chorionic gonadotropin  
BMI  body mass ind ex 
BP blood pressure  
bpm beats per minute  
BUN  blood urea nitrogen  
C positive control  
CANTAB  Cambridge neuropsychological test automated battery  
CFR  Code of Federal Regulations  
CIOMS  Council for International Organizations of Medical Sciences  
CK creatine kinase  
Cmax maximum observed concentration  
CO 2 carbon dioxide (bicarbonate)  
COWS  clinical opi[INVESTIGATOR_791262]  
C-SSRS  Columbia -Suicide Severity Rating Scale  
CT clinical trial  
CTMS  clinical trial management system  
CV coefficient of variation   
CYP  cytochrome P450  
DAI Drug Administration Instruction  
DC discontinuation  
DCT  data collection tool  
DILI  drug-induced liver injury  
DMC  data monitoring committee  
DNA  deoxyribonucleic acid  
PF-[ADDRESS_1090819]  
HIV human immunodeficiency virus  
HRT  hormone replacement therapy  
IB investigator’s brochure  
ICD informed consent document  
ICH International Council for Harmonisation  
IND investigational new drug application  
INR intern ational normalized ratio  
IP investigational product  
IR immediate -release  
IRB institutional review board  
IRC internal review committee  
IRT Interactive Response Technology  
IUD intrauterine device  
IUS intrauterine hormone -releasing system  
IV intraven ous 
IVRS  Interactive Voice Response System  
LFT liver function test  
MCH  mean corpuscular hemoglobin  
MCHC  mean corpuscular hemoglobin concentration  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 94  
 Abbreviation  Term  
MCV  mean corpuscular volume  
MHP  mental health professional  
msec  millisecond  
N/A not applicable  
P placebo 
PCD  primary completion date  
PD pharmacodynamic(s)  
PI [INVESTIGATOR_63168](s)  
PR pulse rate  
PT prothrombin time  
PVC  premature ventricular contraction/complex  
Q1 first quartile  
Q3 third quartile  
QTc corrected QT  
QTcB  corre cted QT (Bazett  method)  
QTcF  corrected QT (Fridericia method)  
qual qualitative  
RBC  red blood cell  
RNA  ribonucleic acid  
RR respi[INVESTIGATOR_791263] 2 oxygen saturation of hemoglobin  
SRSD  single reference safety document  
SToD  study team on demand  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
T gabapentin plus oxycodon e HCl  
Tbili  total bilirubin  
THC  tetrahydrocannabinol  
t.i.d. three times a day  
T1/[ADDRESS_1090820] crossover study evaluating the abuse potential of Neurontin® 
taken orally concomitantly with Oxycodone hydrochloride in healthy non -drug 
dependent, recreational opi[INVESTIGATOR_791264]® (Gabapentin ) 
Protocol Number  A9451180  
Study Type  Phase 4  
Amendment  2.0 
Protocol Date  12 March  2021  
Legal/Fili ng 
Sponsor  Upjohn US [ADDRESS_1090821]  
[LOCATION_001], NY [ZIP_CODE] -5703  
 
 
  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 97  
 Table 8. Summary of changes from  Protocol Amendment 1 dated 24 Dec 2020  to  Protocol Amendment 2 dated 12 March  
2021
Section  
 Old Text ( Protocol Amendment 1 dated 
24 Dec 2020)  New Text (Protocol Amendment 2 dated 12 Mar  
2021)  Rationale for 
amendment  
Section 1.3 Sched ule of 
activities , Table 1  - * C-SSRS Baseline/Screening Version will be used at   
the screening Visit [ADDRESS_1090822] Visit Version will be used.  
 Footnote added to provide 
better clarity  
Section 1.3 Schedule of 
activities , Table 2 - * C-SSRS Si nce Last Visit Version  will be used for all the 
visits  
 Footnote added to provide 
better clarity  
Section 5.2 Exclusion 
Criteria # 10:  Herbal supplements, herbal medications and 
hormone replacement therapy must be 
discontinued at least [ADDRESS_1090823] dose of 
study medication.  
 
(hormone replacement therapy is deleted)  Correction of 
typographical error  
Section [IP_ADDRESS]  Risk 
Assessment During 
Screening  
 Risk assessments should be done by a 
qualified mental health professional (MHP).  
In the [LOCATION_002], a qualified MHP is a 
psychiatrist or a licensed PhD level clinical 
psychologist.  In other countries a qualified 
MHP is a  clinically qualified professional 
with appropriate training in the assessment 
of suicide risk (according to the local 
clinical practice standards and regulations) 
and who would normally evaluate the risk 
for suicide for a participant  Risk assessments shou ld be done by a qualified mental 
health professional (MHP) with appropriate training in 
the assessment of suicide risk (according to the local 
clinical practice standards and regulations)  and who 
would normally evaluate the risk for suicide for a 
participa nt. 
 Text is modified for better 
clarity  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 98 
 Table 9. Summary of changes from Protocol dated 09 Nov 2020 to Protocol Amendment 1 dated 24 Dec 2020  
Section  
 Old Text (Protocol  dated 09 Nov 2020  New Text (Protocol Amendment  1 dated 24 Dec 
2020)  Rationale for 
amendment  
Administrative 
Changes  
Sponsor and Sponsor 
contacts details 
updated  Missing  
 
Sponsor name ‘[COMPANY_007]’  Added  
Upjohn US [ADDRESS_1090824]  
[LOCATION_001], NY [ZIP_CODE] -5703  
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
The sponsor name [CONTACT_366595] ‘[COMPANY_007] ’ to ‘Upjohn’ 
wherever applicable throughout the protocol  The sponsor for this study 
is changed from ‘[COMPANY_007]’ 
to ‘Upjohn US 1 LLC’  
 
Administrativ e changes 
are made to include 
updated Sponsor details 
and authorized sponsor 
protocol approvers  
Section 2.1 Study 
Rationale From (4th 
paragraph):  Epi[INVESTIGATOR_591811], 
particularly among individuals with a history 
of opi[INVESTIGATOR_2554].  Gabapentin abuse is 
reported both alone (ie, without other drugs), 
and in conju nction with opi[INVESTIGATOR_791265] ‘high’ obtained from opi[INVESTIGATOR_2438].1-[ADDRESS_1090825] abuse potential, particularly among 
individuals with a history o f opi[INVESTIGATOR_2554].  Gabapentin 
abuse is reported both alone (ie, without other drugs), 
and in conjunction with opi[INVESTIGATOR_483240] ‘high’ 
obtained from opi[INVESTIGATOR_2438].1-[ADDRESS_1090826] -authorization safety study The changes were made 
for clarificatio n 
(modifying the last 
sentence from “ This study 
will assess the potential 
abuse liability and 
pharmacokinetics of  -----” 
to “As a consequence, the 
FDA has required this 
post-authorization safety 
study (PASS) to evaluate 
gabapentin  in combinat ion 

PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 99 
 benzodiazepi[INVESTIGATOR_1651], and alcohol.4-7  This study 
will assess the potential abuse liability and 
pharmacokinetics of  gabapentin in 
combination with a moderate dose of 
oxyc odone hydrochloride (HCl) compared to 
oxycodone HCl monotherapy and placebo in 
healthy non -drug dependent, recreational 
drug users.  (PASS) to evaluate gabapentin in combination with a 
moderate dose of oxycodone hydrochloride (HCl) 
compared to oxycodone HCl monotherapy and placebo 
in healthy non -drug dependent, recreational drug users.  
Section 5 .2 Exclusion 
Criteria  Participants are heavy smokers (>20 
cigarettes per day) and/or use e -cigarettes, 
pi[INVESTIGATOR_27442], cigars, chewing tobacco, nicotine 
topi[INVESTIGATOR_113040], nicotine gum, or nicotine 
lozenges.  Participants are heavy smokers or users of other types 
of nicotine products (>20 cigarettes equivalents per 
day) Changes are made to 
provide clarification  
 
Section 5.3.2 Caffeine, 
Alcohol, and Tobacco  The use of oral or chewed tobacco and/or 
nicotine -containing products (including 
topi[INVESTIGATOR_113040]) is not permitte d for the 
entire study  The use of oral or chewed tobacco and/or nicotine -
containing products (including topi[INVESTIGATOR_113040]) is not 
permitted from  at least [ADDRESS_1090827] th e typographical 
error  
Section 10.1.5 
Dissemination of 
Clinical Study Data  
 [COMPANY_007] fulfills its commitment to publicly 
disclose clinical study results through 
posting the results of studies on 
www.clinicaltrials.gov  (ClinicalTrials.gov), 
the European Clini cal Trials Database 
(EudraCT), and/or www.pfizer.com and 
other public registries in accordance with 
applicable local laws/regulations.  In 
addition, [COMPANY_007] reports study results outside 
of the requirements of local laws/regulations 
pursuant to its standard operating procedures 
(SOPs).  
 
www.pfizer.com  
 
[COMPANY_007] posts public disclosure synopses 
(CSR synopses in w hich any data that could 
be used to identify individual participants 
have been removed) on www.pfizer.com for 
[COMPANY_007] -sponsored interventional studies at the Upjohn fu lfills its co mmitment to publicly disclose 
clinical study results through posting the results of 
studies on www.clinicaltrials.gov  (ClinicalTrials.gov), 
the European Clinical Trials Database (EudraCT), and 
other public registries in accordance with applica ble 
local law s/regulations.  In addition, Upjohn reports 
study results outside of the requirements of local 
laws/regulations pursuant to its standard operating 
procedures (SOPs).  
 
 
 
 
No information added  This is due to change of 
study sponsor from [COMPANY_007] 
to Upjohn.   
 
 
 
 
 
 
 
 
 
 
This information is 
removed due to change of 
study sponsor from [COMPANY_007] 
to Upjohn  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 100 
  same time the US Basic Results document is 
posted to www.clinicaltrials.gov.  
Section 10.1.10 
Sponsor’s Qualified 
Medical Personnel  Removed  
For sites other than a [COMPANY_007] CRU, the 
contact [CONTACT_791300] a participant calls 
that number, he or she will be directed back 
to the investigator site.  No information added  This statement is removed 
due to change of study 
sponsor from [COMPANY_007] to 
Upjohn.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 101 
 11. REFERENCES   
1. Evoy KE, Morrison MD, Saklad  SR. Abuse  and misuse of pregabalin and gabapentin. 
Drugs 2017; 77(4):403 -26. 
2. Smith RV, Lofwall MR, Havens JR. Abuse and diversion of gabapentin among 
nonmedical prescription opi[INVESTIGATOR_591812]. Am J Psychiatry 2015; 
172(5):[ADDRESS_1090828] 2015; 24(2):[ADDRESS_1090829] frequently involved in drug 
overdose death s: [LOCATION_002], 2011 -2016. Natl Vital Stat Rep 2018; 67(9):1 -14.  
5. Gomes T, Juurlink DN, Antoniou T, et al. Gabapentin, opi[INVESTIGATOR_2438], and the risk of 
opi[INVESTIGATOR_2480] -related death: a population -based nested case -control study. PLoS Med 2017; 
14(10):e1002396.  
6. Hakkinen M , Vuori E,  Kalso E, et al. Profiles of pregabalin and gabapentin abuse by 
[CONTACT_591855]. Forensic Sci Int 2014; 241:1 -6. 
7. Slavova S, Miller A, Bunn TL, et al. Prevalence of gabapentin in drug overdose 
postmortem toxicology testing results. Drug Alco hol Depend  2018; 186(5):80 -5. 
8. Mersfelder TL, Nichols WH. Gabapentin: abuse, dependence, and withdrawal. Ann 
Pharmacother 2016; 50(3):229 -33.  
9. Bonnet U, Scherbaum N. [On the risk of dependence on gabapentinoids]. Fortschr 
Neurol Psychiatr 2018; 86(2):82 -105. 
10. Neuronti n® [package insert ]. [LOCATION_001], NY : Parke -Davis, Division of [COMPANY_007] Inc ; 2017.  
11. Schoedel KA, Szeto I, Setnik B, et al. Abuse potential assessment of cannabidiol (CBD) 
in recreational polydrug users: a randomized, double -blind, controlled trial. Epi [INVESTIGATOR_791266] v 2018; 88(11):162 -71. 
12. Kinnunen M, Pi[INVESTIGATOR_791267] P, Kokki H, et al. Updated clinical pharmacokinetics and 
pharmacodynamics of oxycodone. Clin Pharmacokinet 2019; 58(6):705 -25. 
13. Oxycodone hydrochloride [package insert ]. Newport, KY : Xanodyne® Pharmaceu ticals 
Inc; 2008.  
14. US Department of Health and Human Services, Food and Drug Administration, Center 
for Drug Evaluation and Research (CDER). Assessment of abuse potential of drugs. In: 
Guidance for industry. Silver Spring, MD: Food and Drug Administration;  2017: 34 
pages.  
PF-00345043  
Protocol A9451180  
Protocol Amendment 2, 12 Mar 2021   
 
Upjohn US 1 LLC  CONFIDENTIAL  
Page 102 
 15. Setnik B, Roland C, Pi[INVESTIGATOR_6852] G, et al. Measurement of Drug Liking in Abuse Potential 
Studies: A Comparison of Unipolar and Bipolar Visual Analog Scales. The Journal of 
Clinical Pharmacology 2017, 57(2) 266 –274. 
16. Zacny J, Gutierrez S. Charact erizing th e subjective, psychomotor, and physiological 
effects of oral oxycodone in non -drug-abuse volunteers. Psychopharmacology 
2003;170:242 -54.  DOI 10.1007/s00213 -003-1540 -9.  
17. Guidance for industry: Abuse -Deterrent Opi[INVESTIGATOR_2438] – Evaluation and Labeling. April 2015. 
Available at: https://www.fda.gov/files/drugs/published/Abuse -Deterrent -Opi[INVESTIGATOR_2438] -
Evaluation -and-Labeling.pdf .  